{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T03:19:08Z","timestamp":1783394348700,"version":"3.54.6"},"reference-count":215,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T00:00:00Z","timestamp":1617580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T00:00:00Z","timestamp":1617580800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Herb and Evelyn Abrams Family Amyloid Research Fund.","award":["1"],"award-info":[{"award-number":["1"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammation"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s10753-021-01455-6","type":"journal-article","created":{"date-parts":[[2021,4,6]],"date-time":"2021-04-06T00:02:39Z","timestamp":1617667359000},"page":"1663-1682","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Understanding Accelerated Atherosclerosis in Systemic Lupus Erythematosus: Toward Better Treatment and Prevention"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4478-2441","authenticated-orcid":false,"given":"Allison B.","family":"Reiss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benna","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saba","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven E.","family":"Carsons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"DeLeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,5]]},"reference":[{"issue":"6","key":"1455_CR1","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.coi.2012.10.004","volume":"24","author":"J Choi","year":"2012","unstructured":"Choi, J., S.T. Kim, and J. Craft. 2012. The pathogenesis of systemic lupus erythematosus-an update. Current Opinion in Immunology 24 (6): 651\u2013657.","journal-title":"Current Opinion in Immunology"},{"issue":"1","key":"1455_CR2","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s12519-019-00229-3","volume":"16","author":"L Pan","year":"2020","unstructured":"Pan, L., M.P. Lu, J.H. Wang, M. Xu, and S.R. Yang. 2020. Immunological pathogenesis and treatment of systemic lupus erythematosus. World Journal of Pediatrics 16 (1): 19\u201330.","journal-title":"World Journal of Pediatrics"},{"key":"1455_CR3","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/s41590-020-0677-6","volume":"21","author":"GC Tsokos","year":"2020","unstructured":"Tsokos, G.C. 2020. Autoimmunity and organ damage in systemic lupus erythematosus. Nature Immunology 21: 605\u2013614.","journal-title":"Nature Immunology"},{"issue":"4","key":"1455_CR4","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.semarthrit.2008.10.007","volume":"39","author":"GJ Pons-Estel","year":"2010","unstructured":"Pons-Estel, G.J., G.S. Alarc\u00f3n, L. Scofield, L. Reinlib, and G.S. Cooper. 2010. Understanding the epidemiology and progression of systemic lupus erythematosus. Seminars in Arthritis and Rheumatism 39 (4): 257\u2013268.","journal-title":"Seminars in Arthritis and Rheumatism"},{"issue":"8","key":"1455_CR5","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1002\/art.40512","volume":"70","author":"EY Yen","year":"2018","unstructured":"Yen, E.Y., and R.R. Singh. 2018. Brief Report: Lupus-An Unrecognized Leading Cause of Death in Young Females: A Population-Based Study Using Nationwide Death Certificates, 2000-2015. Arthritis & Rheumatology 70 (8): 1251\u20131255.","journal-title":"Arthritis & Rheumatology"},{"issue":"4","key":"1455_CR6","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1177\/2040622310380100","volume":"1","author":"MB Amissah-Arthur","year":"2010","unstructured":"Amissah-Arthur, M.B., and C. Gordon. 2010. Contemporary treatment of systemic lupus erythematosus: an update for clinicians. Therapeutic Advances in Chronic Disease 1 (4): 163\u2013175.","journal-title":"Therapeutic Advances in Chronic Disease"},{"issue":"22","key":"1455_CR7","doi-asserted-by":"publisher","first-page":"2602","DOI":"10.2174\/1381612826666200211122633","volume":"26","author":"TW Raja","year":"2020","unstructured":"Raja, T.W., D. Veeramuthu, I. Savarimuthu, and N.A. Al-Dhabi. 2020. Current Trends in the Treatment of Systemic Lupus Erythematosus. Current Pharmaceutical Design 26 (22): 2602\u20132609.","journal-title":"Current Pharmaceutical Design"},{"key":"1455_CR8","doi-asserted-by":"crossref","unstructured":"Bernal, C.B., L.D. Zamora LD, and S.V. Navarra. 2015. Biologic therapies in systemic lupus erythematosus. International Journal of Rheumatic Diseases 18(2): 146\u2013153.","DOI":"10.1111\/1756-185X.12490"},{"key":"1455_CR9","doi-asserted-by":"publisher","first-page":"303","DOI":"10.3389\/fmed.2020.00303","volume":"7","author":"LM Wise","year":"2020","unstructured":"Wise, L.M., and W. Stohl. 2020. Belimumab and Rituximab in Systemic Lupus Erythematosus: A Tale of Two B Cell-Targeting Agents. Frontiers in Medicine (Lausanne) 7: 303.","journal-title":"Frontiers in Medicine (Lausanne)"},{"issue":"5","key":"1455_CR10","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1093\/oxfordjournals.aje.a009122","volume":"145","author":"S Manzi","year":"1997","unstructured":"Manzi, S., E.N. Meilahn, J.E. Rairie, C.G. Conte, T.A. Jr Medsger, L. Jansen-McWilliams, R.B. D'Agostino, and L.H. Kuller. 1997. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. American Journal of Epidemiology 145 (5): 408\u2013415.","journal-title":"American Journal of Epidemiology"},{"issue":"4","key":"1455_CR11","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1002\/acr.22173","volume":"66","author":"M Yurkovich","year":"2014","unstructured":"Yurkovich, M., K. Vostretsova, W. Chen, and J.A. Avi\u00f1a-Zubieta. 2014. Overall and cause-specific mortality in patients with systemic lupus erythematosus: a meta-analysis of observational studies. Arthritis Care & Research (Hoboken) 66 (4): 608\u2013616.","journal-title":"Arthritis Care & Research (Hoboken)"},{"issue":"10","key":"1455_CR12","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1002\/acr.24328","volume":"72","author":"M Barbhaiya","year":"2020","unstructured":"Barbhaiya, M., C.H. Feldman, S.K. Chen, H. Guan, M.A. Fischer, B.M. Everett, and K.H. Costenbader. 2020. Comparative Risks of Cardiovascular Disease in Systemic Lupus Erythematosus, Diabetes and General Medicaid Patients. Arthritis Care & Research (Hoboken) 72 (10): 1431\u20131439.","journal-title":"Arthritis Care & Research (Hoboken)"},{"issue":"2","key":"1455_CR13","doi-asserted-by":"publisher","first-page":"116","DOI":"10.2174\/157340308784245775","volume":"4","author":"CB Zeller","year":"2008","unstructured":"Zeller, C.B., and S. Appenzeller. 2008. Cardiovascular disease in systemic lupus erythematosus: the role of traditional and lupus related risk factors. Current Cardiology Reviews 4 (2): 116\u2013122.","journal-title":"Current Cardiology Reviews"},{"issue":"4","key":"1455_CR14","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s11926-016-0571-2","volume":"18","author":"CE Fors Nieves","year":"2016","unstructured":"Fors Nieves, C.E., and P.M. Izmirly. 2016. Mortality in Systemic Lupus Erythematosus: an Updated Review. Current Rheumatology Reports 18 (4): 21.","journal-title":"Current Rheumatology Reports"},{"key":"1455_CR15","doi-asserted-by":"publisher","first-page":"53","DOI":"10.5114\/reum.2015.51502","volume":"2","author":"A Karpi\u0144ska","year":"2015","unstructured":"Karpi\u0144ska, A., and M. Ciurzy\u0144ski. 2015. Coronary artery disease is a significant cause of morbidity and premature death in patients with systemic lupus erythematosus. Reumatologia 2: 53\u201355.","journal-title":"Reumatologia"},{"issue":"12","key":"1455_CR16","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1016\/j.numecd.2019.08.006","volume":"29","author":"SR Ke","year":"2019","unstructured":"Ke, S.R., C.W. Liu, Y.W. Wu, K.R. Lai, C.Y. Wu, J.W. Lin, C.L. Chan, and R.H. Pan. 2019. Systemic lupus erythematosus is associated with poor outcome after acute myocardial infarction. Nutrition, Metabolism & Cardiovascular Diseases 29 (12): 1400\u20131407.","journal-title":"Nutrition, Metabolism & Cardiovascular Diseases"},{"issue":"12","key":"1455_CR17","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1016\/j.jacc.2011.02.005","volume":"57","author":"L Mosca","year":"2011","unstructured":"Mosca, L., E.J. Benjamin, K. Berra, J.L. Bezanson, R.J. Dolor, D.M. Lloyd-Jones, L.K. Newby, I.L. Pi\u00f1a, V.L. Roger, L.J. Shaw, D. Zhao, T.M. Beckie, C. Bushnell, J. D'Armiento, P.M. Kris-Etherton, J. Fang, T.G. Ganiats, A.S. Gomes, C.R. Gracia, C.K. Haan, E.A. Jackson, D.R. Judelson, E. Kelepouris, C.J. Lavie, A. Moore, N.A. Nussmeier, E. Ofili, S. Oparil, P. Ouyang, V.W. Pinn, K. Sherif, S.C. Jr Smith, G. Sopko, N. Chandra-Strobos, E.M. Urbina, V. Vaccarino, and N.K. Wenger. 2011. Effectiveness-based guidelines for the prevention of cardiovascular disease in women--2011 update: a guideline from the American Heart Association. Journals of the American College of Cardiology 57 (12): 1404\u20131423.","journal-title":"Journals of the American College of Cardiology"},{"issue":"2","key":"1455_CR18","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1586\/eci.10.98","volume":"7","author":"M McMahon","year":"2011","unstructured":"McMahon, M., B.H. Hahn, and B.J. Skaggs. 2011. Systemic lupus erythematosus and cardiovascular disease: prediction and potential for therapeutic intervention. Expert Review of Clinical Immunology 7 (2): 227\u2013224.","journal-title":"Expert Review of Clinical Immunology"},{"issue":"10","key":"1455_CR19","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1002\/1529-0131(200110)44:10<2331::AID-ART395>3.0.CO;2-I","volume":"44","author":"JM Esdaile","year":"2001","unstructured":"Esdaile, J.M., M. Abrahamowicz, T.T. Grodzicky, Y. Li, C. Panaritis, R. du Berger, R. C\u00f4te, S.A. Grover, P.R. Fortin, A.E. Clarke, and J.L. Sen\u00e9cal. 2001. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis & Rheumatology 44 (10): 2331\u20132337.","journal-title":"Arthritis & Rheumatology"},{"key":"1455_CR20","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1002\/art.37795","volume":"65","author":"CH Feldman","year":"2013","unstructured":"Feldman, C.H., L.T. Hiraki, J. Liu, M.A. Fischer, D.H. Solomon, G.S. Alarc\u00f3n, W.C. Winkelmayer, and K.H. Costenbader. 2013. Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000-2004. Arthritis & Rheumatology 65: 753\u2013763.","journal-title":"Arthritis & Rheumatology"},{"issue":"8","key":"1455_CR21","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1080\/1744666X.2017.1327352","volume":"13","author":"GJ Pons-Estel","year":"2017","unstructured":"Pons-Estel, G.J., M.F. Ugarte-Gil, and G.S. Alarc\u00f3n. 2017. Epidemiology of systemic lupus erythematosus. Expert Review of Clinical Immunology 13 (8): 799\u2013814.","journal-title":"Expert Review of Clinical Immunology"},{"key":"1455_CR22","doi-asserted-by":"crossref","unstructured":"Borchers, A.T., S.M. Naguwa, Y. Shoenfeld, and M.E. Gershwin. The geoepidemiology of systemic lupus erythematosus. Autoimmunity Reviews 9: A277\u2013A287.","DOI":"10.1016\/j.autrev.2009.12.008"},{"key":"1455_CR23","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1093\/rheumatology\/kex260","volume":"56","author":"F Rees","year":"2017","unstructured":"Rees, F., M. Doherty, M.J. Grainge, P. Lanyon, and W. Zhang. 2017. The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies. Rheumatology (Oxford) 56: 1945\u20131961.","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"1455_CR24","doi-asserted-by":"publisher","first-page":"3159","DOI":"10.1002\/art.11296","volume":"48","author":"IN Bruce","year":"2003","unstructured":"Bruce, I.N., M.B. Urowitz, D.D. Gladman, D. Iba\u00f1ez, and G. Steiner. 2003. Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study. Arthritis & Rheumatology 48 (11): 3159\u20133167.","journal-title":"Arthritis & Rheumatology"},{"key":"1455_CR25","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1002\/1529-0131(199902)42:2<338::AID-ANR17>3.0.CO;2-U","volume":"42","author":"MM Ward","year":"1999","unstructured":"Ward, M.M. 1999. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheumatology 42: 338\u2013346.","journal-title":"Arthritis Rheumatology"},{"key":"1455_CR26","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1146\/annurev-med-060911-090007","volume":"64","author":"JM Kahlenberg","year":"2013","unstructured":"Kahlenberg, J.M., and M.J. Kaplan. 2013. Mechanisms of premature atherosclerosis in rheumatoid arthritis and lupus. Annual Review of Medicine 64: 249\u2013263.","journal-title":"Annual Review of Medicine"},{"issue":"12","key":"1455_CR27","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1016\/j.clinthera.2014.07.021","volume":"36","author":"EL Gilbert","year":"2014","unstructured":"Gilbert, E.L., and M.J. Ryan. 2014. Estrogen in cardiovascular disease during systemic lupus erythematosus. Clinical Therapeutics 36 (12): 1901\u20131912.","journal-title":"Clinical Therapeutics"},{"issue":"2","key":"1455_CR28","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1080\/13697137.2019.1679113","volume":"23","author":"A Gompel","year":"2020","unstructured":"Gompel, A. 2020. Systemic lupus erythematosus and menopause. Climacteric 23 (2): 109\u2013115.","journal-title":"Climacteric"},{"key":"1455_CR29","doi-asserted-by":"publisher","first-page":"635","DOI":"10.3389\/fimmu.2015.00635","volume":"6","author":"D Khan","year":"2016","unstructured":"Khan, D., and A.S. Ansar. 2016. The Immune System Is a Natural Target for Estrogen Action: Opposing Effects of Estrogen in Two Prototypical Autoimmune Diseases. Frontiers in Immunology 6: 635.","journal-title":"Frontiers in Immunology"},{"key":"1455_CR30","unstructured":"Simard, J.F., Rossides, M., Arkema, E.V., Svenungsson, E., Wikstr\u00f6m, A.K., Mittleman, M.A., Salmon, J.E. 2020. Maternal hypertensive disorders in SLE pregnancy and future cardiovascular outcomes. Arthritis Care Research (Hoboken) Epub ahead of print."},{"issue":"11","key":"1455_CR31","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1093\/oxfordjournals.aje.a009400","volume":"147","author":"HS Ros","year":"1998","unstructured":"Ros, H.S., S. Cnattingius, and L. Lipworth. 1998. Comparison of risk factors for preeclampsia and gestational hypertension in a population-based cohort study. American Journal of Epidemiology 147 (11): 1062\u20131070.","journal-title":"American Journal of Epidemiology"},{"key":"1455_CR32","first-page":"7","volume":"8","author":"FA English","year":"2015","unstructured":"English, F.A., L.C. Kenny, and F.P. McCarthy. 2015. Risk factors and effective management of preeclampsia. Integral Blood Pressure Control 8: 7\u201312.","journal-title":"Integral Blood Pressure Control"},{"issue":"10","key":"1455_CR33","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.008337","volume":"7","author":"H Riise","year":"2018","unstructured":"Riise, H., G. Sulo, G.S. Tell, I. Igland, O. Nyg\u00e5rd, A.C. Iversen, and A.K. Daltveit. 2018. Association Between Gestational Hypertension and Risk of Cardiovascular Disease Among 617 589 Norwegian Women. Journal of the American Heart Association 7 (10): e008337.","journal-title":"Journal of the American Heart Association"},{"issue":"24","key":"1455_CR34","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1136\/heartjnl-2020-316541","volume":"106","author":"C Arnott","year":"2020","unstructured":"Arnott, C., M. Nelson, M.A. Ramirez, J. Hyett, M. Gale, A. Henry, D.S. Celermajer, L. Taylor, and M. Woodward. 2020. Maternal cardiovascular risk after hypertensive disorder of pregnancy. Heart 106 (24): 1927\u20131933.","journal-title":"Heart"},{"issue":"2","key":"1455_CR35","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1097\/JCN.0b013e31827f0d53","volume":"29","author":"PK Weinstein","year":"2014","unstructured":"Weinstein, P.K., A. Amirkhosravi, T.J. Angelopoulos, A. Bushy, M.M. Covelli, and K.E. Dennis. 2014. Reducing cardiovascular risk in women with lupus: perception of risk and predictors of risk-reducing behaviors. Journal of Cardiovascular Nursing 29 (2): 130\u2013139.","journal-title":"Journal of Cardiovascular Nursing"},{"issue":"7","key":"1455_CR36","first-page":"735","volume":"5","author":"RI Ja\u00e9n","year":"2020","unstructured":"Ja\u00e9n, R.I., A. Val-Blasco, P. Prieto, M. Gil-Fern\u00e1ndez, T. Smani, J.L. L\u00f3pez-Send\u00f3n, C. Delgado, L. Bosc\u00e1, and M. Fern\u00e1ndez-Velasco. 2020. Innate Immune Receptors, Key Actors in Cardiovascular Diseases. JACC: Basic to Translational Science 5 (7): 735\u2013749.","journal-title":"JACC: Basic to Translational Science"},{"issue":"9","key":"1455_CR37","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/j.jacc.2015.12.048","volume":"67","author":"P Libby","year":"2016","unstructured":"Libby, P., M. Nahrendorf, and F.K. Swirski. 2016. Leukocytes Link Local and Systemic Inflammation in Ischemic Cardiovascular Disease: An Expanded \"Cardiovascular Continuum\". Journals of the American College of Cardiology 67 (9): 1091\u20131103.","journal-title":"Journals of the American College of Cardiology"},{"key":"1455_CR38","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s11926-009-0036-y","volume":"11","author":"AB Reiss","year":"2009","unstructured":"Reiss, A.B. 2009. Effects of inflammation on cholesterol metabolism: Impact on systemic lupus erythematosus. Current Rheumatology Reports 11: 255\u2013260.","journal-title":"Current Rheumatology Reports"},{"issue":"1","key":"1455_CR39","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12944-020-01232-8","volume":"19","author":"B Zhou","year":"2020","unstructured":"Zhou, B., Y. Xia, and J. She. 2020. Dysregulated serum lipid profile and its correlation to disease activity in young female adults diagnosed with systemic lupus erythematosus: a cross-sectional study. Lipids in Health and Disease 19 (1): 40.","journal-title":"Lipids in Health and Disease"},{"key":"1455_CR40","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.semarthrit.2015.10.010","volume":"45","author":"K Tselios","year":"2016","unstructured":"Tselios, K., C. Koumaras, D.D. Gladman, and M.B. Urowitz. 2016. Dyslipidemia in systemic lupus erythematosus: just another comorbidity? Seminars in Arthritis and Rheumatism 45: 604\u2013610.","journal-title":"Seminars in Arthritis and Rheumatism"},{"issue":"5","key":"1455_CR41","doi-asserted-by":"publisher","first-page":"6586","DOI":"10.21608\/ejhm.2018.15588","volume":"73","author":"F Khalil","year":"2018","unstructured":"Khalil, F., M.N. Rafat, N.T. El-Beltagy, and H.A.A.A. Gaber. 2018. Study of dyslipidemia in patients with systemic lupus erythematosus and its correlation to disease activity. Egyptian Journal of Hospital Medicine 73 (5): 6586\u20136595.","journal-title":"Egyptian Journal of Hospital Medicine"},{"issue":"1","key":"1455_CR42","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2019-000332","volume":"6","author":"MM Purmalek","year":"2019","unstructured":"Purmalek, M.M., P.M. Carlucci, A.K. Dey, M. Sampson, Y. Temesgen-Oyelakin, S. Sakhardande, J.B. Lerman, A. Fike, M. Davis, J.H. Chung, T. Salahuddin, Z. Manna, S. Gupta, M.Y. Chen, S. Hasni, N.N. Mehta, A. Remaley, and M.J. Kaplan. 2019. Association of lipoprotein subfractions and glycoprotein acetylation with coronary plaque burden in SLE. Lupus Science & Medicine 6 (1): e000332.","journal-title":"Lupus Science & Medicine"},{"issue":"6","key":"1455_CR43","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1177\/096120339700600610","volume":"6","author":"EF Borba","year":"1997","unstructured":"Borba, E.F., and E. Bonf\u00e1. 1997. Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodies. Lupus 6 (6): 533\u2013539.","journal-title":"Lupus"},{"key":"1455_CR44","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1177\/0961203307081113","volume":"16","author":"MB Urowitz","year":"2007","unstructured":"Urowitz, M.B., D.D. Gladman, D. Ibanez, P. Fortin, J. Sanchez-Guerrero, S. Bae, A. Clarke, S. Bernatsky, C. Gordon, J. Hanly, D. Wallace, D. Isenberg, E. Ginzler, J. Merrill, G. Alarcon, K. Steinsson, M. Petri, M.A. Dooley, I. Bruce, S. Manzi, M. Khamashta, R. Ramsey-Goldman, A. Zoma, G. Sturfelt, O. Nived, P. Maddison, J. Font, R. van Vollenhoven, C. Aranow, K. Kalunian, T. Stoll, and J. Buyon. 2007. Clinical manifestations and coronary artery disease risk factors at diagnosis of systemic lupus erythematosus: data from an international inception cohort. Lupus 16: 731\u2013735.","journal-title":"Lupus"},{"key":"1455_CR45","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1002\/art.23353","volume":"59","author":"MB Urowitz","year":"2008","unstructured":"Urowitz, M.B., D.D. Gladman, D. Ibanez, P. Fortin, J. Sanchez-Guerrero, S. Bae, A. Clarke, S. Bernatsky, C. Gordon, J. Hanly, D. Wallace, D. Isenberg, E. Ginzler, J. Merrill, G.S. Alarc\u00f3n, K. Steinsson, M. Petri, M.A. Dooley, I. Bruce, S. Manzi, M. Khamashta, R. Ramsey-Goldman, A. Zoma, G. Sturfelt, O. Nived, P. Maddison, J. Font, R. van Vollenhoven, C. Aranow, K. Kalunian, and T. Stoll. 2008. Accumulation of coronary artery disease risk factors over three years: data from an international inception cohort. Arthritis & Rheumatology 59: 176\u2013180.","journal-title":"Arthritis & Rheumatology"},{"issue":"2","key":"1455_CR46","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s12026-016-8892-9","volume":"65","author":"MZ Szabo","year":"2017","unstructured":"Szabo, M.Z., P. Szodoray, and E. Kiss. 2017. Dyslipidemia in systemic lupus erythematosus. Immunology Research 65 (2): 543\u2013550.","journal-title":"Immunology Research"},{"key":"1455_CR47","doi-asserted-by":"publisher","first-page":"2957","DOI":"10.1002\/art.10624","volume":"46","author":"M Reichlin","year":"2002","unstructured":"Reichlin, M., J. Fesmire, A.I. Quintero-Del-Rio, and M. Wolfson Reichlin. 2002. Autoantibodies to lipoprotein lipase and dyslipidemia in systemic lupus erythematosus. Arthritis & Rheumatology 46: 2957\u20132963.","journal-title":"Arthritis & Rheumatology"},{"issue":"4","key":"1455_CR48","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1097\/HCO.0000000000000410","volume":"32","author":"PA Gerber","year":"2017","unstructured":"Gerber, P.A., D. Nikolic, and M. Rizzo. 2017. Small, dense LDL: an update. Current Opinion in Cardiology 32 (4): 454\u2013459.","journal-title":"Current Opinion in Cardiology"},{"key":"1455_CR49","doi-asserted-by":"publisher","first-page":"75","DOI":"10.2147\/VHRM.S17015","volume":"7","author":"SO Olusi","year":"2011","unstructured":"Olusi, S.O., and S. George. 2011. Prevalence of LDL atherogenic phenotype in patients with systemic lupus erythematosus. Vascular Health and Risk Management 7: 75\u201380.","journal-title":"Vascular Health and Risk Management"},{"issue":"6","key":"1455_CR50","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1093\/rheumatology\/keg212","volume":"42","author":"SL Nuttall","year":"2003","unstructured":"Nuttall, S.L., S. Heaton, M.K. Piper, U. Martin, and C. Gordon. 2003. Cardiovascular risk in systemic lupus erythematosus\u2014evidence of increased oxidative stress and dyslipidaemia. Rheumatology 42 (6): 758\u2013762.","journal-title":"Rheumatology"},{"issue":"1","key":"1455_CR51","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1002\/art.41059","volume":"72","author":"SY Kim","year":"2020","unstructured":"Kim, S.Y., M. Yu, E.E. Morin, J. Kang, M.J. Kaplan, and A. Schwendeman. 2020. High-Density Lipoprotein in Lupus: Disease Biomarkers and Potential Therapeutic Strategy. Arthritis & Rheumatology 72 (1): 20\u201330.","journal-title":"Arthritis & Rheumatology"},{"key":"1455_CR52","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12944-016-0229-0","volume":"15","author":"K Ga\u00e1l","year":"2016","unstructured":"Ga\u00e1l, K., T. Tarr, H. L\u0151rincz, V. Borb\u00e1s, I. Seres, M. Harangi, P. F\u00fcl\u00f6p, and G. Paragh. 2016. High-density lipopoprotein antioxidant capacity, subpopulation distribution and paraoxonase-1 activity in patients with systemic lupus erythematosus. Lipids in Health and Disease 15: 60.","journal-title":"Lipids in Health and Disease"},{"key":"1455_CR53","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1196\/annals.1422.009","volume":"1108","author":"E Kiss","year":"2007","unstructured":"Kiss, E., I. Seres, T. Tarr, Z. Kocsis, G. Szegedi, and G. Paragh. 2007. Reduced paraoxonase1 activity is a risk for atherosclerosis in patients with systemic lupus erythematosus. Annals of the New York Academy of Sciences 1108: 83\u201391.","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"8","key":"1455_CR54","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1002\/art.24677","volume":"60","author":"M McMahon","year":"2009","unstructured":"McMahon, M., J. Grossman, B. Skaggs, J. Fitzgerald, L. Sahakian, N. Ragavendra, C. Charles-Schoeman, K. Watson, W.K. Wong, E. Volkmann, W. Chen, A. Gorn, G. Karpouzas, M. Weisman, D.J. Wallace, and B.H. Hahn. 2009. Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus. Arthritis & Rheumatology 60 (8): 2428\u20132437.","journal-title":"Arthritis & Rheumatology"},{"issue":"1","key":"1455_CR55","doi-asserted-by":"publisher","first-page":"7295","DOI":"10.1038\/s41598-017-07821-5","volume":"7","author":"MG Carnuta","year":"2017","unstructured":"Carnuta, M.G., C.S. Stancu, L. Toma, G.M. Sanda, L.S. Niculescu, M. Deleanu, A.C. Popescu, M.R. Popescu, A. Vlad, D.R. Dimulescu, M. Simionescu, and A.V. Sima. 2017. Dysfunctional high-density lipoproteins have distinct composition, diminished anti-inflammatory potential and discriminate acute coronary syndrome from stable coronary artery disease patients. Scientific Reports 7 (1): 7295.","journal-title":"Scientific Reports"},{"issue":"45","key":"1455_CR56","doi-asserted-by":"publisher","first-page":"30825","DOI":"10.1074\/jbc.M109.047605","volume":"284","author":"A Undurti","year":"2009","unstructured":"Undurti, A., Y. Huang, J.A. Lupica, J.D. Smith, J.A. DiDonato, and S.L. Hazen. 2009. Modification of high density lipoprotein by myeloperoxidase generates a pro-inflammatory particle. Journal of Biological Chemistry 284 (45): 30825\u201330835.","journal-title":"Journal of Biological Chemistry"},{"issue":"3","key":"1455_CR57","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1136\/annrheumdis-2016-209683","volume":"76","author":"CK Smith","year":"2017","unstructured":"Smith, C.K., N.L. Seto, A. Vivekanandan-Giri, W. Yuan, M.P. Playford, Z. Manna, S.A. Hasni, R. Kuai, N.N. Mehta, A. Schwendeman, S. Pennathur, and M.J. Kaplan. 2017. Lupus high-density lipoprotein induces proinflammatory responses in macrophages by binding lectin-like oxidised low-density lipoprotein receptor 1 and failing to promote activating transcription factor 3 activity. Annals of the Rheumatic Diseases 76 (3): 602\u2013611.","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"2","key":"1455_CR58","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/acr.20076","volume":"62","author":"ER Volkmann","year":"2010","unstructured":"Volkmann, E.R., J.M. Grossman, L.J. Sahakian, B.J. Skaggs, J. FitzGerald, N. Ragavendra, C. Charles-Schoeman, W. Chen, A. Gorn, G. Karpouzas, M. Weisman, D.J. Wallace, B.H. Hahn, and M. McMahon. 2010. Low physical activity is associated with proinflammatory high-density lipoprotein and increased subclinical atherosclerosis in women with systemic lupus erythematosus. Arthritis Care & Research (Hoboken) 62 (2): 258\u2013265.","journal-title":"Arthritis Care & Research (Hoboken)"},{"issue":"9","key":"1455_CR59","doi-asserted-by":"publisher","first-page":"514","DOI":"10.3390\/medicina55090514","volume":"55","author":"AB Reiss","year":"2019","unstructured":"Reiss, A.B., H.A. Arain, L.J. Kasselman, H.A. Renna, J. Zhen, I. Voloshyna, J. DeLeon, S.E. Carsons, and M. Petri. 2019. Human Lupus Plasma Pro-Atherogenic Effects on Cultured Macrophages Are Not Mitigated by Statin Therapy: A Mechanistic LAPS Substudy. Medicina 55 (9): 514.","journal-title":"Medicina"},{"issue":"5","key":"1455_CR60","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s00296-009-1020-6","volume":"30","author":"AB Reiss","year":"2010","unstructured":"Reiss, A.B., K. Anwar, J.T. Merrill, E.S. Chan, N.W. Awadallah, B.N. Cronstein, H. Michael Belmont, E. Belilos, G. Rosenblum, K. Belostocki, L. Bonetti, K. Hasneen, and S.E. Carsons. 2010. Plasma from systemic lupus patients compromises cholesterol homeostasis: a potential mechanism linking autoimmunity to atherosclerotic cardiovascular disease. Rheumatology International 30 (5): 591\u2013598.","journal-title":"Rheumatology International"},{"key":"1455_CR61","doi-asserted-by":"crossref","unstructured":"Reiss, A.B., D.W. Wan, K. Anwar, J.T. Merrill, P.A. Wirkowski, N. Shah, B.N Cronstein, E.S. Chan, and S.E. Carsons. 2009. A BRIEF COMMUNICATION: Enhanced CD36 Scavenger Receptor Expression in THP-1 Human Monocytes in the Presence of Lupus Plasma: Linking Autoimmunity and Atherosclerosis. Experimental Biology and Medicine 234(3): 354\u2013360.","DOI":"10.3181\/0806-BC-194"},{"issue":"14","key":"1455_CR62","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1177\/1535370216647181","volume":"241","author":"I Voloshyna","year":"2016","unstructured":"Voloshyna, I., I. Teboul, M.J. Littlefield, N.M. Siegart, G.K. Turi, M.J. Fazzari, S.E. Carsons, J. DeLeon, and A.B. Reiss. 2016. Resveratrol counters systemic lupus erythematosus-associated atherogenicity by normalizing cholesterol efflux. Experimental Biology and Medicine 241 (14): 1611\u20131619.","journal-title":"Experimental Biology and Medicine"},{"issue":"3","key":"1455_CR63","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.cell.2011.04.005","volume":"145","author":"KJ Moore","year":"2011","unstructured":"Moore, K.J., and I. Tabas. 2011. Macrophages in the pathogenesis of atherosclerosis. Cell 145 (3): 341\u2013355.","journal-title":"Cell"},{"issue":"2","key":"1455_CR64","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1056\/NEJMoa1001689","volume":"364","author":"AV Khera","year":"2011","unstructured":"Khera, A.V., M. Cuchel, M. de la Llera-Moya, A. Rodrigues, M.F. Burke, K. Jafri, B.C. French, J.A. Phillips, M.L. Mucksavage, R.L. Wilensky, E.R. Mohler, G.H. Rothblat, and D.J. Rader. 2011. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. New England Journal of Medicine 364 (2): 127\u2013135.","journal-title":"New England Journal of Medicine"},{"key":"1455_CR65","doi-asserted-by":"publisher","first-page":"2480","DOI":"10.1016\/j.jacc.2016.03.538","volume":"67","author":"P Mody","year":"2016","unstructured":"Mody, P., P.H. Joshi, A. Khera, C.R. Ayers, and A. Rohatgi. 2016. Beyond coronary calcification, family history, and C-reactive protein: cholesterol efflux capacity and cardiovascular risk prediction. Journals of the American College of Cardiology 67: 2480\u20132487.","journal-title":"Journals of the American College of Cardiology"},{"key":"1455_CR66","doi-asserted-by":"crossref","unstructured":"Quevedo-Abeledo, J.C., H. S\u00e1nchez-P\u00e9rez, B. Tejera-Segura, L. de Armas-Rillo, E. Armas-Gonz\u00e1lez, J.D. Machado, M.A. Gonz\u00e1lez-Gay, F. D\u00edaz-Gonz\u00e1lez, and I. Ferraz-Amaro. 2020. Differences in HDL-Cholesterol Efflux Capacity Between Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis. Arthritis Care & Research (Hoboken) Epub ahead of print.","DOI":"10.1002\/acr.24407"},{"key":"1455_CR67","doi-asserted-by":"crossref","unstructured":"S\u00e1nchez-P\u00e9rez, H., J.C. Quevedo-Abeledo, L. de Armas-Rillo, et al. 2020. Impaired HDL cholesterol efflux capacity in systemic lupus erythematosus patients is related to subclinical carotid atherosclerosis. Rheumatology (Oxford) Epub ahead of print.","DOI":"10.1093\/rheumatology\/keaa038"},{"key":"1455_CR68","doi-asserted-by":"crossref","unstructured":"Casey, K.A., M.A. Smith, D. Sinibaldi, N.L. Seto, M.P. Playford, X. Wang, P.M. Carlucci, L. Wang, G. Illei, B. Yu, S. Wang, A.T. Remaley, N.N. Mehta, M.J. Kaplan, and W.I. White. 2020. Modulation of cardiometabolic disease markers by type I interferon inhibition in systemic lupus erythematosus. Arthritis & Rheumatology Epub ahead of print.","DOI":"10.1002\/art.41518"},{"key":"1455_CR69","doi-asserted-by":"publisher","first-page":"7320","DOI":"10.1038\/s41598-017-07574-1","volume":"7","author":"A Mak","year":"2017","unstructured":"Mak, A., N.Y. Kow, H. Schwarz, L. Gong, S.H. Tay, and L.H. Ling. 2017. Endothelial dysfunction in systemic lupus erythematosus \u2013 a case-control study and an updated meta-analysis and meta-regression. Scientific Reports 7: 7320\u20137320.","journal-title":"Scientific Reports"},{"issue":"6","key":"1455_CR70","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/labinvest.2013.61","volume":"93","author":"W Sun","year":"2013","unstructured":"Sun, W., Y. Jiao, B. Cui, X. Gao, Y. Xia, and Y. Zhao. 2013. Immune complexes activate human endothelium involving the cell-signaling HMGB1-RAGE axis in the pathogenesis of lupus vasculitis. Laboratory Investigation 93 (6): 626\u2013638.","journal-title":"Laboratory Investigation"},{"key":"1455_CR71","first-page":"157","volume":"131","author":"JC Oates","year":"2020","unstructured":"Oates, J.C., V. Ramakrishnan, P.J. Nietert, J.D. Spence, T.W. Fleury, M. Markiewicz, D.L. Russell, and M.F. Lopes-Virella. 2020. Associations between accelerated atherosclerosis, oxidized LDL immune complexes, and in vitro endothelial dysfunction in systemic lupus erythematosus. Transactions of the American Clinical and Climatological Association 131: 157\u2013177.","journal-title":"Transactions of the American Clinical and Climatological Association"},{"issue":"3","key":"1455_CR72","doi-asserted-by":"publisher","first-page":"192","DOI":"10.2174\/1574887113666180314091831","volume":"13","author":"D Mauro","year":"2018","unstructured":"Mauro, D., and A. Nerviani. 2018. Endothelial Dysfunction in Systemic Lupus Erythematosus: Pathogenesis, Assessment and Therapeutic Opportunities. Reviews on Recent Clinical Trials 13 (3): 192\u2013198.","journal-title":"Reviews on Recent Clinical Trials"},{"key":"1455_CR73","doi-asserted-by":"publisher","first-page":"8378","DOI":"10.1073\/pnas.92.18.8378","volume":"92","author":"C Lozada","year":"1995","unstructured":"Lozada, C., R.I. Levin, M. Huie, R. Hirschhorn, D. Naime, M. Whitlow, P.A. Recht, B. Golden, and B.N. Cronstein. 1995. Identification of C1q as the heat-labile serum cofactor required for immune complexes to stimulate endothelial expression of the adhesion molecules E-selectin and intercellular and vascular cell adhesion molecules 1. Proceedings of the National Academy of Sciences of the United States of America 92: 8378\u20138382.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"1455_CR74","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1016\/S0022-2275(20)31518-2","volume":"42","author":"AB Reiss","year":"2001","unstructured":"Reiss, A.B., N.W. Awadallah, S.S. Malhotra, M.C. Montesinos, E.S. Chan, N.B. Javitt, and B.N. Cronstein. 2001. Immune complexes and INF-gamma decrease cholesterol 27-hydroxylase in human arterial endothelium and macrophages. Journal of Lipid Research 42: 1913\u20131922.","journal-title":"Journal of Lipid Research"},{"key":"1455_CR75","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1189\/jlb.0204107","volume":"76","author":"AB Reiss","year":"2004","unstructured":"Reiss, A.B., M.M. Rahman, E.S. Chan, M.C. Montesinos, N.W. Awadallah, and B.N. Cronstein. 2004. Adenosine A2A receptor occupancy stimulates expression of proteins involved in reverse cholesterol transport and inhibits foam cell formation in macrophages. Journal of Leukocyte Biology 76: 727\u2013734.","journal-title":"Journal of Leukocyte Biology"},{"issue":"9","key":"1455_CR76","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1002\/acr.23495","volume":"70","author":"M Taraborelli","year":"2017","unstructured":"Taraborelli, M., E. Sciatti, I. Bonadei, V. Terlizzi, M. Fredi, R. Zani, G. Cancarini, A. Tincani, F. Franceschini, E. Vizzardi, and I. Cavazzana. 2017. Endothelial dysfunction in early systemic lupus erythematosus patients and controls without previous cardiovascular events. Arthritis Care & Research (Hoboken) 70 (9): 1277\u20131283.","journal-title":"Arthritis Care & Research (Hoboken)"},{"key":"1455_CR77","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.atherosclerosis.2020.01.028","volume":"297","author":"C Mendoza-Pinto","year":"2020","unstructured":"Mendoza-Pinto, C., A. Rojas-Villarraga, N. Molano-Gonz\u00e1lez, M. Garc\u00eda-Carrasco, P. Mungu\u00eda-Realpozo, I. Etchegaray-Morales, H. Morales-S\u00e1nchez, R. Berra-Romani, and R. Cervera. 2020. Endothelial dysfunction and arterial stiffness in patients with systemic lupus erythematosus: A systematic review and meta-analysis. Atherosclerosis 297: 55\u201363.","journal-title":"Atherosclerosis"},{"issue":"4","key":"1455_CR78","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1161\/ATVBAHA.116.308126","volume":"37","author":"S Nhek","year":"2017","unstructured":"Nhek, S., R. Clancy, K.A. Lee, N.M. Allen, T.J. Barrett, E. Marcantoni, J. Nwaukoni, S. Rasmussen, M. Rubin, J.D. Newman, J.P. Buyon, and J.S. Berger. 2017. Activated Platelets Induce Endothelial Cell Activation via an Interleukin-1\u03b2 Pathway in Systemic Lupus Erythematosus. Arteriosclerosis, Thrombosis, and Vascular Biology 37 (4): 707\u2013716.","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"issue":"12","key":"1455_CR79","doi-asserted-by":"publisher","first-page":"3378","DOI":"10.1172\/JCI27196","volume":"115","author":"M Gawaz","year":"2005","unstructured":"Gawaz, M., H. Langer, and A.E. May. 2005. Platelets in inflammation and atherogenesis. Journal of Clinical Investigation 115 (12): 3378\u20133384.","journal-title":"Journal of Clinical Investigation"},{"issue":"8","key":"1455_CR80","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1002\/art.39656","volume":"68","author":"C Lood","year":"2016","unstructured":"Lood, C., H. Tyd\u00e9n, B. Gullstrand, A. J\u00f6nsen, E. K\u00e4llberg, M. M\u00f6rgelin, R. Kahn, I. Gunnarsson, T. Leanderson, F. Ivars, E. Svenungsson, and A.A. Bengtsson. 2016. Platelet-Derived S100A8\/A9 and Cardiovascular Disease in Systemic Lupus Erythematosus. Arthritis & Rheumatology 68 (8): 1970\u20131980.","journal-title":"Arthritis & Rheumatology"},{"key":"1455_CR81","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/nrrheum.2009.237","volume":"6","author":"JC Hall","year":"2010","unstructured":"Hall, J.C., and A. Rosen. 2010. Type I interferons: crucial participants in disease amplification in autoimmunity. Nature Reviews Rheumatology 6: 40\u201349.","journal-title":"Nature Reviews Rheumatology"},{"issue":"2","key":"1455_CR82","volume":"3","author":"H Tyd\u00e9n","year":"2017","unstructured":"Tyd\u00e9n, H., C. Lood, B. Gullstrand, C.T. Nielsen, N.H.H. Heegaard, R. Kahn, A. J\u00f6nsen, and A.A. Bengtsson. 2017. Endothelial dysfunction is associated with activation of the type I interferon system and platelets in patients with systemic lupus erythematosus. Rheumatic & Musculoskeletal Diseases Open 3 (2): e000508.","journal-title":"Rheumatic & Musculoskeletal Diseases Open"},{"issue":"10","key":"1455_CR83","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1016\/j.jacc.2003.11.061","volume":"43","author":"ES Ford","year":"2004","unstructured":"Ford, E.S., W.H. Giles, and A.H. Mokdad. 2004. The distribution of 10-Year risk for coronary heart disease among US adults: findings from the National Health and Nutrition Examination Survey III. Journals of the American College of Cardiology 43 (10): 1791\u20131796.","journal-title":"Journals of the American College of Cardiology"},{"key":"1455_CR84","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1016\/j.clinthera.2011.09.009","volume":"357","author":"E Sarnes","year":"2011","unstructured":"Sarnes, E., L. Crofford, M. Watson, G. Dennis, H. Kan, and D. Bass. 2011. Incidence and US costs of corticosteroid-associated adverse events: a systematic literature review. Clinical Therapeutics 357: 1413\u20131432.","journal-title":"Clinical Therapeutics"},{"issue":"1","key":"1455_CR85","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.semarthrit.2012.12.002","volume":"43","author":"SR Schoenfeld","year":"2013","unstructured":"Schoenfeld, S.R., S. Kasturi, and K.H. Costenbader. 2013. The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic review. Seminars in Arthritis & Rheumatology 43 (1): 77\u201395.","journal-title":"Seminars in Arthritis & Rheumatology"},{"issue":"8","key":"1455_CR86","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1093\/aje\/kws130","volume":"176","author":"LS Magder","year":"2012","unstructured":"Magder, L.S., and M. Petri. 2012. Incidence of and risk factors for adverse cardiovascular events among patients with systemic lupus erythematosus. American Journal of Epidemiology 176 (8): 708\u2013719.","journal-title":"American Journal of Epidemiology"},{"issue":"12","key":"1455_CR87","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.3899\/jrheum.161121","volume":"44","author":"K Tselios","year":"2017","unstructured":"Tselios, K., D.D. Gladman, J. Su, O. Ace, and M.B. Urowitz. 2017. Evolution of Risk Factors for Atherosclerotic Cardiovascular Events in Systemic Lupus Erythematosus: A Longterm Prospective Study. Journal of Rheumatology 44 (12): 1841\u20131849.","journal-title":"Journal of Rheumatology"},{"issue":"5","key":"1455_CR88","first-page":"663","volume":"45","author":"J Romero-Diaz","year":"2012","unstructured":"Romero-Diaz, J., R.I. Acosta-Hern\u00e1ndez, S. Criales-Vera, E. Kimura-Hayama, M. Dom\u00ednguez-Quintana, R. Mor\u00e1n-Contla, C. N\u00fa\u00f1ez-Alvarez, P. Lara-Reyes, C. Aguilar-Salinas, and J. S\u00e1nchez-Guerrero. 2012. Systemic lupus erythematosus risk factors for coronary artery calcifications. Rheumatology (Oxford) 45 (5): 663\u2013670.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"1455_CR89","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/1529-0131(199901)42:1<51::AID-ANR7>3.0.CO;2-D","volume":"42","author":"S Manzi","year":"1999","unstructured":"Manzi, S., F. Selzer, K. Sutton-Tyrrell, S.G. Fitzgerald, J.E. Rairie, R.P. Tracy, and L.H. Kuller. 1999. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis & Rheumatology 42 (1): 51\u201360.","journal-title":"Arthritis & Rheumatology"},{"issue":"25","key":"1455_CR90","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1056\/NEJMoa035471","volume":"349","author":"MJ Roman","year":"2003","unstructured":"Roman, M.J., B.A. Shanker, A. Davis, M.D. Lockshin, L. Sammaritano, R. Simantov, M.K. Crow, J.E. Schwartz, S.A. Paget, R.B. Devereux, and J.E. Salmon. 2003. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. [published correction appears in The New England Journal of Medicine 2006 355(16): 1746]. The New England Journal of Medicine 349 (25): 2399\u20132406.","journal-title":"The New England Journal of Medicine"},{"issue":"3","key":"1455_CR91","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1093\/rheumatology\/ker339","volume":"51","author":"Z Touma","year":"2012","unstructured":"Touma, Z., D.D. Gladman, D. Iba\u00f1ez, and M.B. Urowitz. 2012. Ability of non-fasting and fasting triglycerides to predict coronary artery disease in lupus patients. Rheumatology (Oxford) 51 (3): 528\u2013534.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"1455_CR92","doi-asserted-by":"publisher","first-page":"R156","DOI":"10.1186\/ar3473","volume":"13","author":"M Nikpour","year":"2011","unstructured":"Nikpour, M., M.B. Urowitz, D. Ibanez, P.J. Harvey, and D.D. Gladman. 2011. Importance of cumulative exposure to elevated cholesterol and blood pressure in development of atherosclerotic coronary artery disease in systemic lupus erythematosus: a prospective proof-of-concept cohort study. Arthritis Research & Therapy 13 (5): R156.","journal-title":"Arthritis Research & Therapy"},{"issue":"4","key":"1455_CR93","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1177\/0961203311425524","volume":"21","author":"C Bengtsson","year":"2012","unstructured":"Bengtsson, C., M.L. Ohman, O. Nived, and S. Rantap\u00e4\u00e4 Dahlqvist. 2012. Cardiovascular event in systemic lupus erythematosus in northern Sweden: incidence and predictors in a 7-year follow-up study. Lupus 21 (4): 452\u2013459.","journal-title":"Lupus"},{"key":"1455_CR94","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s10067-018-4286-9","volume":"38","author":"S Fasano","year":"2019","unstructured":"Fasano, S., D.P.E. Margiotta, L. Pierro, L. Navarini, A. Riccardi, A. Afeltra, and G. Valentini. 2019. Prolonged remission is associated with a reduced risk of cardiovascular disease in patients with systemic lupus erythematosus: a GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) study. Clinical Rheumatology 38: 457\u2013463.","journal-title":"Clinical Rheumatology"},{"issue":"1","key":"1455_CR95","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s00467-010-1640-9","volume":"26","author":"S Sule","year":"2011","unstructured":"Sule, S., B. Fivush, A. Neu, and S. Furth. 2011. Increased risk of death in pediatric and adult patients with ESRD secondary to lupus. Pediatric Nephrology 26 (1): 93\u201398.","journal-title":"Pediatric Nephrology"},{"issue":"7","key":"1455_CR96","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1002\/art.21967","volume":"54","author":"JM Von Feldt","year":"2006","unstructured":"Von Feldt, J.M., L.V. Scalzi, A.J. Cucchiara, S. Morthala, C. Kealey, S.D. Flagg, A. Genin, A.L. Van Dyke, E. Nackos, A. Chander, E. Gehrie, R.Q. Cron, and A.S. Whitehead. 2006. Homocysteine levels and disease duration independently correlate with coronary artery calcification in patients with systemic lupus erythematosus. Arthritis & Rheumatology 54 (7): 2220\u20132227.","journal-title":"Arthritis & Rheumatology"},{"issue":"4","key":"1455_CR97","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0174572","volume":"12","author":"JT Gustafsson","year":"2017","unstructured":"Gustafsson, J.T., M. Herlitz Lindberg, I. Gunnarsson, S. Pettersson, K. Elvin, J. \u00d6hrvik, A. Larsson, K. Jensen-Urstad, and E. Svenungsson. 2017. Excess atherosclerosis in systemic lupus erythematosus,-A matter of renal involvement: Case control study of 281 SLE patients and 281 individually matched population controls. PLOS One 12 (4): e0174572.","journal-title":"PLOS One"},{"issue":"11","key":"1455_CR98","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1136\/ard.62.11.1071","volume":"62","author":"A Doria","year":"2003","unstructured":"Doria, A., Y. Shoenfeld, R. Wu, P.F. Gambari, M. Puato, A. Ghirardello, B. Gilburd, S. Corbanese, M. Patnaik, S. Zampieri, J.B. Peter, E. Favaretto, L. Iaccarino, Y. Sherer, S. Todesco, and P. Pauletto. 2003. Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Annals of the Rheumatic Diseases 62 (11): 1071\u20131077.","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"3","key":"1455_CR99","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.rdc.2014.04.003","volume":"40","author":"M McMahon","year":"2014","unstructured":"McMahon, M., and B. Skaggs. 2014. Pathogenesis and treatment of atherosclerosis in lupus. Rheumatic Diseases Clinics of North America 40 (3): 475\u2013495 viii.","journal-title":"Rheumatic Diseases Clinics of North America"},{"issue":"2","key":"1455_CR100","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1194\/jlr.M600361-JLR200","volume":"48","author":"S Tsimikas","year":"2007","unstructured":"Tsimikas, S., E.S. Brilakis, R.J. Lennon, E.R. Miller, J.L. Witztum, J.P. McConnell, K.S. Kornman, and P.B. Berger. 2007. Relationship of IgG and IgM autoantibodies to oxidized low density lipoprotein with coronary artery disease and cardiovascular events. Journal of Lipid Research 48 (2): 425\u2013433.","journal-title":"Journal of Lipid Research"},{"issue":"2","key":"1455_CR101","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/rheumatology\/kez264","volume":"59","author":"P L\u00f3pez","year":"2020","unstructured":"L\u00f3pez, P., J. Rodr\u00edguez-Carrio, A. Mart\u00ednez-Zapico, \u00c1.I. P\u00e9rez-\u00c1lvarez, L. Benavente, L. Caminal-Montero, and A. Su\u00e1rez. 2020. IgM anti-phosphorylcholine antibodies associate with senescent and IL-17+ T cells in SLE patients with a pro-inflammatory lipid profile. Rheumatology (Oxford) 59 (2): 407\u2013417.","journal-title":"Rheumatology (Oxford)"},{"key":"1455_CR102","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","volume":"4","author":"S Miyakis","year":"2006","unstructured":"Miyakis, S., M.D. Lockshin, T. Atsumi, D.W. Branch, R.L. Brey, R. Cervera, R.H. Derksen, P.G.D.E. Groot, T. Koike, P.L. Meroni, G. Reber, Y. Shoenfeld, A. Tincani, P.G. Vlachoyiannopoulos, and S.A. Krilis. 2006. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). Journal of Thrombosis and Haemostasis 4: 295\u2013306.","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"1455_CR103","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1161\/01.CIR.99.17.2227","volume":"99","author":"J George","year":"1999","unstructured":"George, J., D. Harats, B. Gilburd, A. Afek, Y. Levy, J. Schneiderman, I. Barshack, J. Kopolovic, and Y. Shoenfeld. 1999. Immunolocalization of beta2-glycoprotein I (apolipoprotein H) to human atherosclerotic plaques: potential implications for lesion progression. Circulation 99: 2227\u20132230.","journal-title":"Circulation"},{"key":"1455_CR104","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1161\/ATVBAHA.113.302680","volume":"34","author":"F Conti","year":"2014","unstructured":"Conti, F., F.R. Spinelli, C. Alessandri, M. Pacelli, F. Ceccarelli, E. Marocchi, A. Montali, A. Capozzi, B. Buttari, E. Profumo, M. Sorice, M. Arca, G. Valesini, and R. Rigan\u00f2. 2014. Subclinical atherosclerosis in systemic lupus erythematosus and antiphospholipid syndrome: focus on beta2GPI-specific T cell response. Arteriosclerosis, Thrombosis, and Vascular Biology 34: 661\u2013668.","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"1455_CR105","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.5551\/jat.24372","volume":"21","author":"X Zhang","year":"2014","unstructured":"Zhang, X., Y. Xie, H. Zhou, Y. Xu, J. Liu, H. Xie, and J. Yan. 2014. Involvement of TLR4 in oxidized LDL\/beta2GPI\/anti-beta2GPI-induced transformation of macrophages to foam cells. Journal of Atherosclerosis and Thrombosis 21: 1140\u20131151.","journal-title":"Journal of Atherosclerosis and Thrombosis"},{"key":"1455_CR106","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1194\/jlr.M200329-JLR200","volume":"44","author":"K Kobayashi","year":"2003","unstructured":"Kobayashi, K., M. Kishi, T. Atsumi, M.L. Bertolaccini, H. Makino, N. Sakairi, I. Yamamoto, T. Yasuda, M.A. Khamashta, G.R. Hughes, T. Koike, D.R. Voelker, and E. Matsuura. 2003. Circulating oxidized LDL forms complexes with beta2-glycoprotein I: implication as an atherogenic autoantigen. Journal of Lipid Research 44: 716\u2013726.","journal-title":"Journal of Lipid Research"},{"issue":"1","key":"1455_CR107","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1078\/0171-2985-00214","volume":"207","author":"E Matsuura","year":"2003","unstructured":"Matsuura, E., K. Kobayashi, T. Koike, Y. Shoenfeld, M.A. Khamashtab, and G.R.V. Hughes. 2003. Atherogenic autoantigen-oxidized LDL complexes with \u03b22-glycoprotein I. Immunobiology 207 (1): 17\u201322.","journal-title":"Immunobiology"},{"issue":"5","key":"1455_CR108","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/ar2527","volume":"10","author":"JM Von Feldt","year":"2008","unstructured":"Von Feldt, J.M. 2008. High-density lipoprotein: does it have a dark side? Arthritis Research & Therapy 10 (5): 121.","journal-title":"Arthritis Research & Therapy"},{"issue":"8","key":"1455_CR109","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1002\/art.21976","volume":"54","author":"M McMahon","year":"2006","unstructured":"McMahon, M., J. Grossman, J. FitzGerald, E. Dahlin-Lee, D.J. Wallace, B.Y. Thong, H. Badsha, K. Kalunian, C. Charles, M. Navab, A.M. Fogelman, and B.H. Hahn. 2006. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis & Rheumatology 54 (8): 2541\u20132549.","journal-title":"Arthritis & Rheumatology"},{"key":"1455_CR110","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3899\/jrheum.150460","volume":"43","author":"K Tselios","year":"2016","unstructured":"Tselios, K., B.J. Sheane, D.D. Gladman, and M.B. Urowitz. 2016. Optimal monitoring for coronary heart disease risk in patients with systemic lupus erythematosus: a systematic review. Journal of Rheumatology 43: 54\u201365.","journal-title":"Journal of Rheumatology"},{"key":"1455_CR111","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.ypmed.2006.06.017","volume":"43","author":"SD Persell","year":"2006","unstructured":"Persell, S.D., D.M. Lloyd-Jones, and D.W. Baker. 2006. National Cholesterol Education Program risk assessment and potential for risk misclassification. Preventive Medicine 43: 368\u2013371.","journal-title":"Preventive Medicine"},{"key":"1455_CR112","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.107.699579","volume":"117","author":"RB D\u2019Agostino Sr","year":"2008","unstructured":"D\u2019Agostino, R.B., Sr., R.S. Vasan, M.J. Pencina, P.A. Wolf, M. Cobain, J.M. Massaro, and W.B. Kannel. 2008. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 117: 743\u2013753.","journal-title":"Circulation"},{"key":"1455_CR113","doi-asserted-by":"publisher","first-page":"75","DOI":"10.2217\/ijr.09.73","volume":"5","author":"C Skamra","year":"2010","unstructured":"Skamra, C., and R. Ramsey-Goldman. 2010. Management of cardiovascular complications in systemic lupus erythematosus. International Journal of Clinical Rheumatology 5: 75\u2013100.","journal-title":"International Journal of Clinical Rheumatology"},{"issue":"1","key":"1455_CR114","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2017-000212","volume":"4","author":"D Boulos","year":"2017","unstructured":"Boulos, D., R.L. Koelmeyer, E.F. Morand, and Y. Hoi. 2017. Cardiovascular risk profiles in a lupus cohort: what do different calculators tell us? Lupus Science & Medicine 4 (1): e000212.","journal-title":"Lupus Science & Medicine"},{"key":"1455_CR115","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.3899\/jrheum.090011","volume":"36","author":"RJ Goldberg","year":"2009","unstructured":"Goldberg, R.J., M.B. Urowitz, D. Ibanez, M. Nikpour, and D.D. Gladman. 2009. Risk factors for development of coronary artery disease in women with systemic lupus erythematosus. Journal of Rheumatology 36: 2454\u20132461.","journal-title":"Journal of Rheumatology"},{"issue":"25 Pt B","key":"1455_CR116","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1016\/j.jacc.2013.11.005","volume":"63","author":"DC Goff Jr","year":"2014","unstructured":"Goff, D.C., Jr., D.M. Lloyd-Jones, G. Bennett, S. Coady, R.B. D\u2019Agostino Sr., R. Gibbons, P. Greenland, D.T. Lackland, D. Levy, C.J. O\u2019Donnell, J.G. Robinson, J.S. Schwartz, S.T. Shero, S.C. Smith Jr., P. Sorlie, N.J. Stone, and P.W.F. Wilson. 2014. ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. Journals of the American College of Cardiology 63 (25 Pt B): 2935\u20132959.","journal-title":"Journals of the American College of Cardiology"},{"key":"1455_CR117","doi-asserted-by":"publisher","first-page":"j2099","DOI":"10.1136\/bmj.j2099","volume":"357","author":"J Hippisley-Cox","year":"2017","unstructured":"Hippisley-Cox, J., C. Coupland, and P. Brindle. 2017. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ (Clinical research ed.) 357: j2099.","journal-title":"BMJ (Clinical research ed.)"},{"issue":"4","key":"1455_CR118","first-page":"602","volume":"38","author":"M Di Battista","year":"2020","unstructured":"Di Battista, M., C. Tani, E. Elefante, D. Chimera, L. Carli, F. Ferro, C. Stagnaro, and M. Mosca. 2020. Framingham, ACC\/AHA or QRISK3: which is the best in systemic lupus erythematosus cardiovascular risk estimation? Clinical and Experimental Rheumatology 38 (4): 602\u2013608.","journal-title":"Clinical and Experimental Rheumatology"},{"issue":"Suppl 1","key":"1455_CR119","first-page":"A107","volume":"7","author":"S Ajeganova","year":"2020","unstructured":"Ajeganova, S., I. Hafstr\u00f6m, and J. Frosteg\u00e5d. 2020. P160\u00a0Risk of CV events and mortality in SLE is associated with accumulated disease-damage, anti-phospholipid syndrome and higher carotid intima-media thickness. Lupus Science & Medicine 7 (Suppl 1): A107\u2013A108.","journal-title":"Lupus Science & Medicine"},{"key":"1455_CR120","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1136\/annrheumdis-2018-214603","volume":"78","author":"S Ajeganova","year":"2019","unstructured":"Ajeganova, S., I. Hafstr\u00f6m, and J. Frosteg\u00e5rd. 2019. THU0256 Risk of long-term incident cardiovascular event and mortality in patients with SLE and population controls is associated with a higher carotid intima-media thickness. Annals of the Rheumatic Diseases 78: 406.","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"7","key":"1455_CR121","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/j.amjcard.2013.05.040","volume":"112","author":"AM Kao","year":"2013","unstructured":"Kao, A.M., A. Lertratanakul, J.R. Elliott, A. Sattar, L. Santelices, P. Shaw, M. Birru, Z. Avram, T. Thompson, K. Sytton-Tyrrell, R. Ramsey-Goldman, and S. Manzi. 2013. Relation of carotid intima-media thickness and plaque with incident cardiovascular events in women with systemic lupus erythematosus. American Journal of Cardiology 112 (7): 1025\u20131032.","journal-title":"American Journal of Cardiology"},{"key":"1455_CR122","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1161\/CIRCULATIONAHA.106.628875","volume":"115","author":"MW Lorenz","year":"2007","unstructured":"Lorenz, M.W., H.S. Marku, M.L. Bots, R. Maria, and M. Sitzer. 2007. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 115: 459\u2013467.","journal-title":"Circulation"},{"issue":"25","key":"1455_CR123","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1056\/NEJMoa035611","volume":"349","author":"Y Asanuma","year":"2003","unstructured":"Asanuma, Y., A. Oeser, A.K. Shintani, E. Turner, N. Olsen, S. Fazio, M.F. Linton, P. Raggi, and C.M. Stein. 2003. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. New England Journal of Medicine 349 (25): 2407\u20132415.","journal-title":"New England Journal of Medicine"},{"key":"1455_CR124","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/0140-6736(92)93147-F","volume":"340","author":"DS Celermajer","year":"1992","unstructured":"Celermajer, D.S., K.E. Sorensen, V.M. Gooch, D.J. Spieghelhalter, O.I. Miller, I.D. Sullivan, J.K. Lloyd, and J.E. Deanfield. 1992. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 340: 1111\u20131115.","journal-title":"Lancet"},{"key":"1455_CR125","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1161\/CIRCULATIONAHA.109.864801","volume":"120","author":"J Yeboah","year":"2009","unstructured":"Yeboah, J., A.R. Folsom, G.L. Burke, C. Johnson, J.F. Polak, W. Post, J.A. Lima, J.R. Crouse, and D.M. Herrington. 2009. Predictive value of brachial flow-mediated dilation for incident cardiovascular events in a population-based study: the multi-ethnic study of atherosclerosis. Circulation 120: 502\u2013509.","journal-title":"Circulation"},{"key":"1455_CR126","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1097\/01.hjh.0000249684.76296.4f","volume":"24","author":"T Inoue","year":"2006","unstructured":"Inoue, T., and K. Node. 2006. Vascular failure: a new clinical entity for vascular disease. Journal of Hypertension 24: 2121\u20132130.","journal-title":"Journal of Hypertension"},{"key":"1455_CR127","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S0735-1097(01)01746-6","volume":"39","author":"MC Corretti","year":"2002","unstructured":"Corretti, M.C., T.J. Anderson, E.J. Benjamin, D. Celermajer, F. Charbonneau, M.A. Creager, J. Deanfield, H. Drexler, M. Gerhard-Herman, D. Herrington, P. Vallance, J. Vita, and R. Vogel. 2002. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. Journals of the American College of Cardiology 39: 257\u2013265.","journal-title":"Journals of the American College of Cardiology"},{"issue":"11","key":"1455_CR128","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1160\/TH17-03-0221","volume":"117","author":"P L\u00f3pez","year":"2017","unstructured":"L\u00f3pez, P., J. Rodr\u00edguez-Carrio, A. Mart\u00ednez-Zapico, A. P\u00e9rez-\u00c1lvarez, R. L\u00f3pez-Mej\u00edas, L. Benavente, L. Mozo, L. Caminal-Montero, M.A. Gonz\u00e1lez-Gay, and A. Su\u00e1rez. 2017. Serum Levels of Anti-PON1 and Anti-HDL Antibodies as Potential Biomarkers of Premature Atherosclerosis in Systemic Lupus Erythematosus. Journal of Thrombosis and Haemostasis 117 (11): 2194\u20132206.","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"7","key":"1455_CR129","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1093\/rheumatology\/keaa016","volume":"59","author":"P L\u00f3pez","year":"2020","unstructured":"L\u00f3pez, P., J. Rodr\u00edguez-Carrio, A. Mart\u00ednez-Zapico, A.I. P\u00e9rez-\u00c1lvarez, S. Su\u00e1rez-D\u00edaz, L. Mozo, L. Benavente, L. Caminal-Montero, and A. Su\u00e1rez. 2020. Low-density granulocytes and monocytes as biomarkers of cardiovascular risk in systemic lupus erythematosus. Rheumatology 59 (7): 1752\u20131764.","journal-title":"Rheumatology"},{"key":"1455_CR130","doi-asserted-by":"crossref","unstructured":"Ganjali, S., A.M. Jr. Gotto, M. Ruscica, S.L. Atkin, A.E. Butler, M. Banach, and A. Sahebkar. 2018. Monocyte-to-HDL-cholesterol ratio as a prognostic marker in cardiovascular diseases. Journal of Cellular Physiology 233(12): 9237-9246.","DOI":"10.1002\/jcp.27028"},{"issue":"1","key":"1455_CR131","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2019-000321","volume":"6","author":"M McMahon","year":"2019","unstructured":"McMahon, M., B. Skaggs, J. Grossman, W.K. Wong, L. Sahakian, W. Chen, and B. Hahn. 2019. Comparison of PREDICTS atherosclerosis biomarker changes after initiation of new treatments in patients with SLE. Lupus Science & Medicine 6 (1): e000321.","journal-title":"Lupus Science & Medicine"},{"key":"1455_CR132","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.cyto.2018.08.002","volume":"111","author":"D Chougule","year":"2018","unstructured":"Chougule, D., M. Nadkar, K. Venkataraman, A. Rajadhyaksha, N. Hase, T. Jamale, S. Kini, P. Khadilkar, V. Anand, M. Madkaikar, and V. Pradhan. 2018. Adipokine interactions promote the pathogenesis of systemic lupus erythematosus. Cytokine 111: 20\u201327.","journal-title":"Cytokine"},{"issue":"7","key":"1455_CR133","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/j.numecd.2020.03.020","volume":"30","author":"F Carbone","year":"2020","unstructured":"Carbone, F., F. Montecucco, A. Poggi, F.F. Nobili, A. Afeltra Cacciapaglia, T. Moccetti, and B.M. Colombo. 2020. Serum adiponectin levels are associated with presence of carotid plaque in women with systemic lupus erythematosus. Nutrition, Metabolism & Cardiovascular Diseases 30 (7): 1147\u20131151.","journal-title":"Nutrition, Metabolism & Cardiovascular Diseases"},{"issue":"11","key":"1455_CR134","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1136\/annrheumdis-2018-213661","volume":"77","author":"L Winau","year":"2018","unstructured":"Winau, L., R.H. Baydes, A. Braner, U. Drott, H. Burkhardt, S. Sangle, D.P. D'Cruz, G. Carr-White, M. Marber, K. Schnoes, C. Arendt, K. Klingel, T.J. Vogl, A.M. Zeiher, E. Nagel, and V.O. Puntmann. 2018. High-sensitive troponin is associated with subclinical imaging biosignature of inflammatory cardiovascular involvement in systemic lupus erythematosus. Annals of the rheumatic diseases 77 (11): 1590\u20131598.","journal-title":"Annals of the rheumatic diseases"},{"issue":"1","key":"1455_CR135","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s13075-017-1352-7","volume":"19","author":"G Divard","year":"2017","unstructured":"Divard, G., R. Abbas, C. Chenevier-Gobeaux, N. Chanson, B. Escoubet, M.P. Chauveheid, A. Dossier, T. Papo, M. Dehoux, and K. Sacre. 2017. High-sensitivity cardiac troponin T is a biomarker for atherosclerosis in systemic lupus erythematous patients: a cross-sectional controlled study. Arthritis Research & Therapy 19 (1): 132.","journal-title":"Arthritis Research & Therapy"},{"issue":"1","key":"1455_CR136","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1002\/art.38204","volume":"66","author":"M McMahon","year":"2014","unstructured":"McMahon, M., B.J. Skaggs, J.M. Grossman, L. Sahakian, J. Fitzgerald, W.K. Wong, E.V. Lourenco, N. Ragavendra, C. Charles-Schoeman, A. Gorn, G.A. Karpouzas, M.B. Taylor, K.E. Watson, M.H. Weisman, D.J. Wallace, and B.H. Hahn. 2014. A panel of biomarkers is associated with increased risk of the presence and progression of atherosclerosis in women with systemic lupus erythematosus. Arthritis & Rheumatology 66 (1): 130\u2013139.","journal-title":"Arthritis & Rheumatology"},{"issue":"5","key":"1455_CR137","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1097\/BOR.0000000000000528","volume":"30","author":"Y Liu","year":"2018","unstructured":"Liu, Y., and M.J. Kaplan. 2018. Cardiovascular disease in systemic lupus erythematosus: an update. Current Opinion in Rheumatology 30 (5): 441\u2013448.","journal-title":"Current Opinion in Rheumatology"},{"issue":"4","key":"1455_CR138","doi-asserted-by":"publisher","first-page":"262","DOI":"10.3389\/fmed.2017.00262","volume":"29","author":"V Teixeira","year":"2018","unstructured":"Teixeira, V., and L.S. Tam. 2018. Novel Insights in Systemic Lupus Erythematosus and Atherosclerosis. Frontiers in Medicine (Lausanne) 29 (4): 262.","journal-title":"Frontiers in Medicine (Lausanne)"},{"issue":"1","key":"1455_CR139","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2017-000239","volume":"4","author":"Z Touma","year":"2017","unstructured":"Touma, Z., and D.D. Gladman. 2017. Current and future therapies for SLE: obstacles and recommendations for the development of novel treatments. Lupus Science & Medicine 4 (1): e000239.","journal-title":"Lupus Science & Medicine"},{"key":"1455_CR140","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1002\/acr.22591","volume":"67","author":"DJ Tunnicliffe","year":"2015","unstructured":"Tunnicliffe, D.J., D. Singh-Grewal, S. Kim, J.C. Craig, and A. Tong. 2015. Diagnosis, monitoring, and treatment of systemic lupus erythematosus: a systematic review of clinical practice guidelines. Arthritis Care & Research 67: 1440\u20131452.","journal-title":"Arthritis Care & Research"},{"issue":"5","key":"1455_CR141","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s11940-000-0045-7","volume":"2","author":"MG Navarrete","year":"2000","unstructured":"Navarrete, M.G., and R.L. Brey. 2000. Neuropsychiatric systemic lupus erythematosus. Current Treatment Options in Neurology 2 (5): 473\u2013485.","journal-title":"Current Treatment Options in Neurology"},{"key":"1455_CR142","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2174\/157015911796557984","volume":"9","author":"A Popescu","year":"2011","unstructured":"Popescu, A., and A.H. Kao. 2011. Neuropsychiatric Systemic Lupus Erythematosus. Current Neuropharmacology 9: 449\u2013457.","journal-title":"Current Neuropharmacology"},{"issue":"5","key":"1455_CR143","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1097\/BOR.0b013e328363eba3","volume":"25","author":"JS Knight","year":"2013","unstructured":"Knight, J.S., and M.J. Kaplan. 2013. Cardiovascular disease in lupus: insights and updates. Current Opinion in Rheumatology 25 (5): 597\u2013605.","journal-title":"Current Opinion in Rheumatology"},{"key":"1455_CR144","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1136\/ard.2010.136762","volume":"70","author":"MA Petri","year":"2011","unstructured":"Petri, M.A., A.N. Kiani, W. Post, L. Christopher-Stine, and L.S. Magder. 2011. Lupus Atherosclerosis Prevention Study (LAPS). Annals of the Rheumatic Diseases 70: 760\u2013765.","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"suppl_1","key":"1455_CR145","first-page":"i114","volume":"56","author":"D Apostolopoulos","year":"2017","unstructured":"Apostolopoulos, D., and E.F. Morand. 2017. It hasn't gone away: the problem of glucocorticoid use in lupus remains. Rheumatology (Oxford) 56 (suppl_1): i114\u2013i122.","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"1455_CR146","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1002\/art.23196","volume":"58","author":"T Thompson","year":"2008","unstructured":"Thompson, T., K. Sutton-Tyrrell, R.P. Wildman, A. Kao, S.G. Fitzgerald, B. Shook, R.P. Tracy, L.H. Kuller, S. Brockwell, and S. Manzi. 2008. Progression of carotid intima-media thickness and plaque in women with systemic lupus erythematosus. Arthritis & Rheumatology 58 (3): 835\u2013842.","journal-title":"Arthritis & Rheumatology"},{"issue":"3","key":"1455_CR147","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.autrev.2017.01.009","volume":"16","author":"MG Tektonidou","year":"2017","unstructured":"Tektonidou, M.G., E. Kravvariti, G. Konstantonis, N. Tentolouris, P.P. Sfikakis, and A. Protogerou. 2017. Subclinical atherosclerosis in systemic lupus erythematosus: comparable risk with diabetes mellitus and rheumatoid arthritis. Autoimmunity Reviews 16 (3): 308\u2013312.","journal-title":"Autoimmunity Reviews"},{"issue":"6","key":"1455_CR148","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1097\/BOR.0000000000000743","volume":"32","author":"G Ruiz-Irastorza","year":"2020","unstructured":"Ruiz-Irastorza, G., D. Mart\u00edn-Iglesias, and A. Soto-Peleteiro. 2020. Update on antimalarials and systemic lupus erythematosus. Current Opinion in Rheumatology 32 (6): 572\u2013582.","journal-title":"Current Opinion in Rheumatology"},{"issue":"1","key":"1455_CR149","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/1756-185X.13159","volume":"21","author":"H Babary","year":"2018","unstructured":"Babary, H., X. Liu, Y. Ayatollahi, X.P. Chen, L. Doo, L.K. Uppaluru, M.K. Kwak, C. Kulaga, D. Modjinou, E. Olech, and J.W. Yoo. 2018. Favorable effects of hydroxychloroquine on serum low density lipid in patients with systemic lupus erythematosus: A systematic review and meta-analysis. International Journal of Rheumatic Diseases 21 (1): 84\u201392.","journal-title":"International Journal of Rheumatic Diseases"},{"key":"1455_CR150","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.mehy.2016.04.045","volume":"93","author":"L Sun","year":"2016","unstructured":"Sun, L., M. Liu, R. Li, Q. Zhao, J. Liu, Y. Yang, L. Zhang, X. Bai, Y. Wei, Q. Ma, J. Zhou, Z. Yuan, and Y. Wu. 2016. Hydroxychloroquine, a promising choice for coronary artery disease? Medical Hypotheses 93: 5\u20137.","journal-title":"Medical Hypotheses"},{"issue":"4","key":"1455_CR151","doi-asserted-by":"publisher","first-page":"745","DOI":"10.3899\/jrheum.150437","volume":"43","author":"L Durcan","year":"2016","unstructured":"Durcan, L., D.A. Winegar, M.A. Connelly, J.D. Otvos, L.S. Magder, and M. Petri. 2016. Longitudinal Evaluation of Lipoprotein Variables in Systemic Lupus Erythematosus Reveals Adverse Changes with Disease Activity and Prednisone and More Favorable Profiles with Hydroxychloroquine Therapy. Journal of Rheumatology 43 (4): 745\u2013750.","journal-title":"Journal of Rheumatology"},{"issue":"10188","key":"1455_CR152","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1016\/S0140-6736(19)30546-X","volume":"393","author":"T D\u00f6rner","year":"2019","unstructured":"D\u00f6rner, T., and R. Furie. 2019. Novel paradigms in systemic lupus erythematosus. Lancet 393 (10188): 2344\u20132358.","journal-title":"Lancet"},{"issue":"1_suppl","key":"1455_CR153","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1177\/0961203396005001051","volume":"5","author":"M Petri","year":"1996","unstructured":"Petri, M. 1996. Hydroxychloroquine use in the Baltimore lupus cohort: effects on lipids, glucose and thrombosis. Lupus 5 (1_suppl): 16\u201322.","journal-title":"Lupus"},{"issue":"6","key":"1455_CR154","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.3899\/jrheum.090994","volume":"37","author":"SK Penn","year":"2010","unstructured":"Penn, S.K., A.H. Kao, L.L. Schott, J.R. Elliott, F.G.S. Toledo, L. Kuller, S. Manzi, and M.C. Wasko. 2010. Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus. Journal of Rheumatology 37 (6): 1136\u20131142.","journal-title":"Journal of Rheumatology"},{"issue":"2","key":"1455_CR155","first-page":"325","volume":"26","author":"P Rahman","year":"1999","unstructured":"Rahman, P., D.D. Gladman, M.B. Urowitz, K. Yuen, D. Hallett, and I.N. Bruce. 1999. The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs. Journal of Rheumatology 26 (2): 325\u2013330.","journal-title":"Journal of Rheumatology"},{"issue":"3","key":"1455_CR156","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1002\/art.27289","volume":"62","author":"H Jung","year":"2010","unstructured":"Jung, H., R. Bobba, J. Su, Z. Shariati-Sarabi, D.D. Gladman, M. Urowitz, W. Lou, and P.R. Fortin. 2010. The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Arthritis & Rheumatology 62 (3): 863\u2013868.","journal-title":"Arthritis & Rheumatology"},{"issue":"12","key":"1455_CR157","doi-asserted-by":"publisher","first-page":"4380","DOI":"10.1161\/01.CIR.96.12.4380","volume":"96","author":"MH Edwards","year":"1997","unstructured":"Edwards, M.H., S. Pierangeli, X. Liu, J.H. Barker, G. Anderson, and E.N. Harris. 1997. Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice. Circulation 96 (12): 4380\u20134384.","journal-title":"Circulation"},{"key":"1455_CR158","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s11926-010-0141-y","volume":"13","author":"M Petri","year":"2011","unstructured":"Petri, M. 2011. Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody positive patients. Current Rheumatology Reports 13: 77\u201380.","journal-title":"Current Rheumatology Reports"},{"issue":"4","key":"1455_CR159","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1161\/01.HYP.37.4.1075","volume":"37","author":"F Selzer","year":"2001","unstructured":"Selzer, F., K. Sutton-Tyrrell, S. Fitzgerald, R. Tracy, L. Kuller, and S. Manzi. 2001. Vascular stiffness in women with systemic lupus erythematosus. Hypertension 37 (4): 1075\u20131082.","journal-title":"Hypertension"},{"issue":"7","key":"1455_CR160","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.numecd.2014.01.006","volume":"24","author":"E Ammirati","year":"2014","unstructured":"Ammirati, E., E.P. Bozzolo, R. Contri, A. Baragetti, A.G. Palini, D. Cianflone, M. Banfi, P. Uboldi, G. Bottoni, I. Scotti, A. Pirillo, L. Grigore, K. Garlaschelli, C. Monaco, A.L. Catapano, M.G. Sabbadini, A.A. Manfredi, and G.D. Norata. 2014. Cardiometabolic and immune factors associated with increased common carotid artery intima-media thickness and cardiovascular disease in patients with systemic lupus erythematosus. Nutrition, Metabolism & Cardiovascular Diseases 24 (7): 751\u2013759.","journal-title":"Nutrition, Metabolism & Cardiovascular Diseases"},{"key":"1455_CR161","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1196\/annals.1422.003","volume":"1108","author":"A Tanay","year":"2007","unstructured":"Tanay, A., E. Leibovitz, A. Frayman, R. Zimlichman, M. Shargorodsky, and D. Gavish. 2007. Vascular elasticity of systemic lupus erythematosus patients is associated with steroids and hydroxychloroquine treatment. Annals of the New York Academy of Sciences 1108: 24\u201334.","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"14","key":"1455_CR162","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1177\/0961203317722847","volume":"26","author":"S Fasano","year":"2017","unstructured":"Fasano, S., D.P. Margiotta, L. Navarini, L. Pierro, I. Pantano, A. Riccardi, A. Afeltra, and G. Valentini. 2017. Primary prevention of cardiovascular disease in patients with systemic lupus erythematosus: case series and literature review. Lupus 26 (14): 1463\u20131472.","journal-title":"Lupus"},{"key":"1455_CR163","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.3899\/jrheum.161351","volume":"44","author":"S Fasano","year":"2017","unstructured":"Fasano, S., L. Pierro, I. Pantano, M. Iudici, and G. Valentini. 2017. Longterm hydroxychloroquine therapy and low-dose aspirin may have an additive effectiveness in the primary prevention of cardiovascular events in patients with systemic lupus erythematosus. Journal of Rheumatology 44: 1032\u20131038.","journal-title":"Journal of Rheumatology"},{"issue":"2","key":"1455_CR164","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1177\/1074248414546324","volume":"20","author":"S Achuthan","year":"2015","unstructured":"Achuthan, S., J. Ahluwalia, N. Shafiq, A. Bhalla, A. Pareek, N. Chandurkar, and S. Malhotra. 2015. Hydroxychloroquine's Efficacy as an Antiplatelet Agent Study in Healthy Volunteers: A Proof of Concept Study. Journal of Cardiovascular Pharmacology and Therapeutics 20 (2): 174\u2013180.","journal-title":"Journal of Cardiovascular Pharmacology and Therapeutics"},{"issue":"1","key":"1455_CR165","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.atherosclerosis.2010.01.043","volume":"211","author":"SI van Leuven","year":"2010","unstructured":"van Leuven, S.I., D.F. van Wijk, O.L. Volger, J.P. de Vries, C.M. van der Loos, D.V. de Kleijn, A.J. Horrevoets, P.P. Tak, A.C. van der Wal, O.J. de Boer, G. Pasterkamp, M.R. Hayden, J.J. Kastelein, and E.S. Stroes. 2010. Mycophenolate mofetil attenuates plaque inflammation in patients with symptomatic carotid artery stenosis. Atherosclerosis 211 (1): 231\u2013236.","journal-title":"Atherosclerosis"},{"issue":"3","key":"1455_CR166","first-page":"353","volume":"71","author":"W Olejarz","year":"2014","unstructured":"Olejarz, W., D. Bryk, and D. Zapolska-Downar. 2014. Mycophenolate mofetil--a new atheropreventive drug? Acta Poloniae Pharmaceutica 71 (3): 353\u2013361.","journal-title":"Acta Poloniae Pharmaceutica"},{"issue":"3","key":"1455_CR167","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1136\/annrheumdis-2011-200071","volume":"71","author":"SI van Leuven","year":"2012","unstructured":"van Leuven, S.I., Y.V. Mendez-Fernandez, A.J. Wilhelm, N.S. Wade, C.L. Gabriel, J.J. Kastelein, E.S. Stroes, P.P. Tak, and A.S. Major. 2012. Mycophenolate mofetil but not atorvastatin attenuates atherosclerosis in lupus-prone LDLr(\u2212\/\u2212) mice. Annals of the Rheumatic Diseases 71 (3): 408\u2013414.","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"9","key":"1455_CR168","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.3389\/fimmu.2018.02658","volume":"16","author":"M Vukelic","year":"2018","unstructured":"Vukelic, M., Y. Li, and V.C. Kyttaris. 2018. Novel Treatments in Lupus. Frontiers in Immunology 16 (9): 2658.","journal-title":"Frontiers in Immunology"},{"issue":"2019","key":"1455_CR169","first-page":"8142368","volume":"18","author":"D Samotij","year":"2019","unstructured":"Samotij, D., and A. Reich. 2019. Biologics in the Treatment of Lupus Erythematosus: A Critical Literature Review. BioMed Research International 18 (2019): 8142368.","journal-title":"BioMed Research International"},{"issue":"1","key":"1455_CR170","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/joim.12529","volume":"281","author":"AA Bengtsson","year":"2017","unstructured":"Bengtsson, A.A., and L. R\u00f6nnblom. 2017. Systemic lupus erythematosus: still a challenge for physicians. Journal of Internal Medicine 281 (1): 52\u201364.","journal-title":"Journal of Internal Medicine"},{"issue":"1","key":"1455_CR171","doi-asserted-by":"publisher","first-page":"e000261","DOI":"10.1136\/lupus-2018-000261","volume":"5","author":"JM Riggs","year":"2018","unstructured":"Riggs, J.M., R.N. Hanna, B. Rajan, K. Zerrouki, J.L. Karnell, D. Sagar, I. Vainshtein, E. Farmer, K. Rosenthal, C. Morehouse, M. de Los Reyes, K. Schifferli, M. Liang, M.A. Sanjuan, G.P. Sims, and R. Kolbeck. 2018. Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus. Lupus Science & Medicine 5 (1): e000261\u2013e000261.","journal-title":"Lupus Science & Medicine"},{"issue":"3","key":"1455_CR172","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1912196","volume":"382","author":"EF Morand","year":"2020","unstructured":"Morand, E.F., R. Furie, Y. Tanaka, I.N. Bruce, A.D. Askanase, C. Richez, S.C. Bae, P.Z. Brohawn, L. Pineda, A. Berglind, and R. Tummala. 2020. Trial of anifrolumab in active systemic lupus erythematosus. The New England Journal of Medicine 382 (3): 211\u2013221.","journal-title":"The New England Journal of Medicine"},{"issue":"3","key":"1455_CR173","first-page":"211","volume":"382","author":"B Goulden","year":"2020","unstructured":"Goulden, B., and D. Isenberg. 2020. Anti-IFN\u03b1R Mabs for the treatment of Systemic Lupus Erythematosus. Expert Opinion on Biological Therapy 382 (3): 211\u2013221.","journal-title":"Expert Opinion on Biological Therapy"},{"issue":"1","key":"1455_CR174","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/nrd.2017.267","volume":"17","author":"DM Schwartz","year":"2017","unstructured":"Schwartz, D.M., Y. Kanno, A. Villarino, M. Ward, M. Gadina, and J.J. O'Shea. 2017. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nature Reviews Drug Discovery 17 (1): 78.","journal-title":"Nature Reviews Drug Discovery"},{"key":"1455_CR175","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nrrheum.2015.167","volume":"12","author":"DM Schwartz","year":"2016","unstructured":"Schwartz, D.M., M. Bonelli, M. Gadina, and J.J. O\u2019Shea. 2016. Type I\/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nature Reviews Rheumatology 12: 25\u201336.","journal-title":"Nature Reviews Rheumatology"},{"key":"1455_CR176","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1189\/jlb.5A0416-194R","volume":"101","author":"A Goropev\u0161ek","year":"2017","unstructured":"Goropev\u0161ek, A., M. Gorenjak, S. Gradi\u0161nik, K. Dai, I. Holc, R. Hojs, I. Krajnc, A. Pahor, and T. Av\u010din. 2017. STAT5 phosphorylation in CD4 T cells from patients with SLE is related to changes in their subsets and follow-up disease severity. Journal of Leukocyte Biology 101: 1405\u20131418.","journal-title":"Journal of Leukocyte Biology"},{"issue":"1","key":"1455_CR177","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1080\/13543784.2019.1551358","volume":"28","author":"CC Mok","year":"2019","unstructured":"Mok, C.C. 2019. The Jakinibs in systemic lupus erythematosus: progress and prospects. Expert Opinion on Investigational Drugs 28 (1): 85\u201392.","journal-title":"Expert Opinion on Investigational Drugs"},{"key":"1455_CR178","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/S0140-6736(18)31363-1","volume":"392","author":"DJ Wallace","year":"2018","unstructured":"Wallace, D.J., R.A. Furie, Y. Tanaka, K.C. Kalunian, M. Mosca, M.A. Petri, T. D\u00f6rner, M.H. Cardiel, I.N. Bruce, E. Gomez, T. Carmack, A.M. DeLozier, J.M. Janes, M.D. Linnik, S. de Bono, M.E. Silk, and R.W. Hoffman. 2018. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet 392: 222\u2013231.","journal-title":"Lancet"},{"issue":"1","key":"1455_CR179","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1002\/art.39818","volume":"69","author":"Y Furumoto","year":"2017","unstructured":"Furumoto, Y., C.K. Smith, L. Blanco, W. Zhao, S.R. Brooks, S.G. Thacker, Z. Abdalrahman, G. Scium\u00e8, W.L. Tsai, A.M. Trier, L. Nunez, L. Mast, V. Hoffmann, A.T. Remaley, J.J. O'Shea, M.J. Kaplan, and M. Gadina. 2017. Tofacitinib Ameliorates Murine Lupus and Its Associated Vascular Dysfunction. Arthritis & Rheumatology 69 (1): 148\u2013160.","journal-title":"Arthritis & Rheumatology"},{"key":"1455_CR180","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3389\/fimmu.2020.00195","volume":"11","author":"YJ Park","year":"2020","unstructured":"Park, Y.J., S.A. Yoo, M. Kim, and W.U. Kim. 2020. The Role of Calcium-Calcineurin-NFAT Signaling Pathway in Health and Autoimmune Diseases. Frontiers in Immunology 11: 195.","journal-title":"Frontiers in Immunology"},{"issue":"3","key":"1455_CR181","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.berh.2017.09.010","volume":"31","author":"CC Mok","year":"2017","unstructured":"Mok, C.C. 2017. Calcineurin inhibitors in systemic lupus erythematosus. Best Practice & Research: Clinical Rheumatology 31 (3): 429\u2013438.","journal-title":"Best Practice & Research: Clinical Rheumatology"},{"key":"1455_CR182","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1097\/BOR.0000000000000311","volume":"28","author":"S Narain","year":"2016","unstructured":"Narain, S., and R. Furie. 2016. Update on clinical trials in systemic lupus erythematosus. Current Opinion in Rheumatology 28: 477\u2013487.","journal-title":"Current Opinion in Rheumatology"},{"key":"1455_CR183","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1136\/annrheumdis-2014-206456","volume":"75","author":"CC Mok","year":"2016","unstructured":"Mok, C.C., K.Y. Ying, C.W. Yim, Y.P. Siu, K.H. Tong, C.H. To, and W.L. Ng. 2016. Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up. Annals of the Rheumatic Diseases 75: 30\u201336.","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"1","key":"1455_CR184","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3109\/14397595.2013.852838","volume":"24","author":"K Oryoji","year":"2014","unstructured":"Oryoji, K., C. Kiyohara, T. Horiuchi, H. Tsukamoto, H. Niiro, T. Shimoda, K. Akashi, and T. Yanase. 2014. Reduced carotid intima-media thickness in systemic lupus erythematosus patients treated with cyclosporine A. Modern Rheumatology 24 (1): 86\u201392.","journal-title":"Modern Rheumatology"},{"key":"1455_CR185","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1177\/0961203311411347","volume":"12","author":"S Sazliyana","year":"2011","unstructured":"Sazliyana, S., M.S. Mohd Shahrir, C.T. Kong, H.J. Tan, B.B. Hamidon, and M.T. Azmi. 2011. Implications of immunosuppressive agents in cardiovascular risks and carotid intima media thickness among lupus nephritis patients. Lupus 12: 1260\u20131266.","journal-title":"Lupus"},{"key":"1455_CR186","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s00011-019-01262-8","volume":"68","author":"I Voloshyna","year":"2019","unstructured":"Voloshyna, I., I. Teboul, L.J. Kasselman, M. Salama, S.E. Carsons, J. DeLeon, J. Mattana, N. Miyawaki, and A.B. Reiss. 2019. Macrophage lipid accumulation in the presence of immunosuppressive drugs mycophenolate mofetil and cyclosporin A. Inflammation Research 68: 787\u2013799.","journal-title":"Inflammation Research"},{"key":"1455_CR187","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/nrrheum.2016.186","volume":"12","author":"GC Tsokos","year":"2016","unstructured":"Tsokos, G.C., M.S. Lo, P. Costa Reis, and K.E. Sullivan. 2016. New insights into the immunopathogenesis of systemic lupus erythematosus. Nature Reviews Rheumatology 12: 716\u2013730.","journal-title":"Nature Reviews Rheumatology"},{"issue":"7","key":"1455_CR188","doi-asserted-by":"publisher","first-page":"316","DOI":"10.3389\/fmed.2020.00316","volume":"9","author":"I Parodis","year":"2020","unstructured":"Parodis, I., M. Stockfelt, and C. Sj\u00f6wall. 2020. B Cell Therapy in Systemic Lupus Erythematosus: From Rationale to Clinical Practice. Frontiers in Medicine (Lausanne) 9 (7): 316.","journal-title":"Frontiers in Medicine (Lausanne)"},{"issue":"11","key":"1455_CR189","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/nrrheum.2016.158","volume":"12","author":"T D\u00f6rner","year":"2016","unstructured":"D\u00f6rner, T., and P.E. Lipsky. 2016. Beyond pan-B-cell-directed therapy - new avenues and insights into the pathogenesis of SLE. Nature Reviews Rheumatology 12 (11): 645\u2013657.","journal-title":"Nature Reviews Rheumatology"},{"key":"1455_CR190","first-page":"961203320965707","volume":"20","author":"MM Bela","year":"2020","unstructured":"Bela, M.M., G. Espinosa, and R. Cervera. 2020. Next stop in the treatment of refractory systemic lupus erythematosus: B-cell targeted combined therapy. Lupus 20: 961203320965707.","journal-title":"Lupus"},{"key":"1455_CR191","doi-asserted-by":"crossref","unstructured":"Do., R.K., E. Hatada, H. Lee, M.R. Tourigny, D. Hilbert, and S. Chen-Kiang. 2000. Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response. Journal of Experimental Medicine 192(7): 953-964.","DOI":"10.1084\/jem.192.7.953"},{"issue":"4","key":"1455_CR192","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0060430","volume":"8","author":"T Kyaw","year":"2013","unstructured":"Kyaw, T., P. Cui, C. Tay, P. Kanellakis, H. Hosseini, E. Liu, A.G. Rolink, P. Tipping, A. Bobik, and B.H. Toh. 2013. BAFF receptor mAb treatment ameliorates development and progression of atherosclerosis in hyperlipidemic ApoE\u2212\/\u2212 mice. PLOS One 8 (4): e60430.","journal-title":"PLOS One"},{"issue":"7","key":"1455_CR193","doi-asserted-by":"publisher","first-page":"4410","DOI":"10.4049\/jimmunol.1000033","volume":"185","author":"T Kyaw","year":"2010","unstructured":"Kyaw, T., C. Tay, A. Khan, V. Dumouchel, A. Cao, K. To, M. Kehry, R. Dunn, A. Agrotis, P. Tipping, A. Bobik, and B.H. Toh. 2010. Conventional B2 B cell depletion ameliorates whereas its adoptive transfer aggravates atherosclerosis. Journal of Immunology 185 (7): 4410\u20134419.","journal-title":"Journal of Immunology"},{"issue":"5","key":"1455_CR194","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1097\/MOL.0b013e32834adaf3","volume":"22","author":"T Kyaw","year":"2011","unstructured":"Kyaw, T., P. Tipping, B.H. Toh, and A. Bobik. 2011. Current understanding of the role of B cell subsets and intimal and adventitial B cells in atherosclerosis. Current Opinion in Lipidology 22 (5): 373\u2013379.","journal-title":"Current Opinion in Lipidology"},{"issue":"2","key":"1455_CR195","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1002\/art.41485","volume":"73","author":"F Saidoune","year":"2021","unstructured":"Saidoune, F., G. Even, Y. Lamri, J. Chezel, A.T. Gaston, B. Escoubet, T. Papo, N. Charles, A. Nicoletti, and K. Sacre. 2021. Effects of BAFF Neutralization on Atherosclerosis Associated With Systemic Lupus Erythematosus. Arthritis & Rheumatology 73 (2): 255\u2013264.","journal-title":"Arthritis & Rheumatology"},{"issue":"9","key":"1455_CR196","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.1002\/art.23764","volume":"58","author":"P Kahn","year":"2008","unstructured":"Kahn, P., M. Ramanujam, R. Bethunaickan, W. Huang, H. Tao, M.P. Madaio, S.M. Factor, and A. Davidson. 2008. Prevention of murine antiphospholipid syndrome by BAFF blockade. Arthritis & Rheumatology 58 (9): 2824\u20132834.","journal-title":"Arthritis & Rheumatology"},{"issue":"1","key":"1455_CR197","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/rheumatology\/kel148","volume":"46","author":"MJ Leandro","year":"2007","unstructured":"Leandro, M.J., N. Cooper, G. Cambridge, M.R. Ehrenstein, and J.C. Edwards. 2007. Bone marrow B-lineage cells in patients with rheumatoid arthritis following rituximab therapy. Rheumatology 46 (1): 29\u201336.","journal-title":"Rheumatology"},{"key":"1455_CR198","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1093\/rheumatology\/kex395","volume":"57","author":"EM McCarthy","year":"2018","unstructured":"McCarthy, E.M., E. Sutton, S. Nesbit, J. White, B. Parker, D. Jayne, B. Griffiths, D.A. Isenberg, A. Rahman, C. Gordon, D.P. D'Cruz, B. Rhodes, P. Lanyon, E.M. Vital, C.S. Yee, C.J. Edwards, L.S. Teh, M. Akil, N.J. McHugh, A. Zoma, and I.N. Bruce. 2018. Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus assessment group biologics register. Rheumatology 57: 470\u2013479.","journal-title":"Rheumatology"},{"key":"1455_CR199","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2016-000163","volume":"3","author":"M Ryden-Aulin","year":"2016","unstructured":"Ryden-Aulin, M., D. Boumpas, I. Bultink, J.L. Callejas Rubio, L. Caminal-Montero, A. Castro, A. Colodro Ruiz, A. Doria, T. D\u00f6rner, C. Gonzalez-Echavarri, E. Gremese, F.A. Houssiau, T. Huizinga, M. Inan\u00e7, D. Isenberg, A. Iuliano, S. Jacobsen, J. Jimen\u00e9z-Alonso, L. Kov\u00e1cs, X. Mariette, M. Mosca, O. Nived, J. Oristrell, M. Ramos-Casals, J. Rasc\u00f3n, G. Ruiz-Irastorza, L. S\u00e1ez-Comet, G. Salvador Cervell\u00f3, G.D. Sebastiani, D. Squatrito, G. Sz\u00fccs, A. Voskuyl, and R. van Vollenhoven. 2016. Off-label use of rituximab for systemic lupus erythematosus in Europe. Lupus Science & Medicine 3: e000163.","journal-title":"Lupus Science & Medicine"},{"issue":"4","key":"1455_CR200","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1093\/rheumatology\/kep446","volume":"49","author":"JM Pego-Reigosa","year":"2010","unstructured":"Pego-Reigosa, J.M., T.Y. Lu, M.F. Fontanillo, V.D. Campo-P\u00e9rez, A. Rahman, and D.A. Isenberg. 2010. Long-term improvement of lipid profile in patients with refractory systemic lupus erythematosus treated with B-cell depletion therapy: a retrospective observational study. Rheumatology 49 (4): 691\u2013696.","journal-title":"Rheumatology"},{"key":"1455_CR201","doi-asserted-by":"crossref","unstructured":"Cacciapaglia, F., Perniola, S., Venerito, V., Anelli, M.G., H\u00e4rdfeldt, J., Fornaro, M., Moschetta, A., Iannone, F. 2020. The Impact of Biologic Drugs on High-Density Lipoprotein Cholesterol Efflux Capacity in Rheumatoid Arthritis Patients. Journal of Clinical Rheumatology Publish Ahead of Print.","DOI":"10.1097\/RHU.0000000000001657"},{"issue":"12","key":"1455_CR202","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s11883-017-0685-7","volume":"19","author":"M Garshick","year":"2017","unstructured":"Garshick, M., and J.A. Underberg. 2017. The Use of Primary Prevention Statin Therapy in Those Predisposed to Atherosclerosis. Current Atherosclerosis Reports 19 (12): 48.","journal-title":"Current Atherosclerosis Reports"},{"issue":"12","key":"1455_CR203","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1177\/0961203313492871","volume":"22","author":"L Iaccarino","year":"2013","unstructured":"Iaccarino, L., S. Bettio, M. Zen, L. Nalotto, M. Gatto, R. Ramonda, L. Punzi, and A. Doria. 2013. Premature coronary heart disease in SLE: can we prevent progression? Lupus 22 (12): 1232\u20131242.","journal-title":"Lupus"},{"key":"1455_CR204","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1136\/ard.2011.155622","volume":"71","author":"HJ de Jong","year":"2012","unstructured":"de Jong, H.J., O.H. Klungel, L. van Dijk, R.J. Vandebriel, H.G. Leufkens, J.W. van der Laan, J.W. Cohen Tervaert, and H.U. van Loveren. 2012. Use of statins is associated with an increased risk of rheumatoid arthritis. Annals of the Rheumatic Diseases 71: 648\u2013654.","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"6","key":"1455_CR205","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1084\/jem.20021425","volume":"197","author":"O Aktas","year":"2003","unstructured":"Aktas, O., S. Waiczies, A. Smorodchenko, J. Dorr, B. Seeger, T. Prozorovski, S. Sallach, M. Endres, S. Brocke, R. Nitsch, and F. Zipp. 2003. Treatment of relapsing paralysis in experimental encephalomyelitis by targeting 1 cells through atorvastatin. Journal of Experimental Medicine 197 (6): 725\u2013733.","journal-title":"Journal of Experimental Medicine"},{"issue":"3","key":"1455_CR206","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.4049\/jimmunol.170.3.1524","volume":"170","author":"BP Leung","year":"2003","unstructured":"Leung, B.P., N. Sattar, A. Crilly, M. Prach, D.W. McCarey, H. Payne, R. Madhok, C. Campbell, J.A. Gracie, F.Y. Liew, and I.B. McInnes. 2003. A novel anti-inflammatory role for simvastatin in inflammatory arthritis. Journal of Immunology 170 (3): 1524\u20131530.","journal-title":"Journal of Immunology"},{"issue":"1-2","key":"1455_CR207","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S0009-8981(03)00321-8","volume":"338","author":"ZM Xu","year":"2003","unstructured":"Xu, Z.M., S.P. Zhao, Q.Z. Li, S. Nie, and H.N. Zhou. 2003. Atorvastatin reduces plasma MCP-1 in patients with acute coronary syndrome. Clinica Chimica Acta 338 (1-2): 17\u201324.","journal-title":"Clinica Chimica Acta"},{"issue":"2","key":"1455_CR208","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1161\/01.CIR.101.2.171","volume":"101","author":"CH Chen","year":"2000","unstructured":"Chen, C.H., W. Jiang, D.P. Via, S. Luo, T.R. Li, Y.T. Lee, and P.D. Henry. 2000. Oxidized low-density lipoproteins inhibit endothelial cell proliferation by suppressing basic Fibroblast growth factor expression. Circulation 101 (2): 171\u2013177.","journal-title":"Circulation"},{"issue":"4","key":"1455_CR209","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1177\/0961203316662719","volume":"26","author":"R Castejon","year":"2016","unstructured":"Castejon, R., A. Casta\u00f1eda, A. Sollet, S. Mellor-Pita, P. Tutor-Ureta, C. Jimenez-Ortiz, and M. Yebra-Bango. 2016. Short-term atorvastatin therapy improves arterial stiffness of middle-aged systemic lupus erythematosus patients with pathological pulse wave velocity. Lupus 26 (4): 355\u2013364.","journal-title":"Lupus"},{"key":"1455_CR210","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1093\/rheumatology\/kem186","volume":"46","author":"GA Ferreira","year":"2007","unstructured":"Ferreira, G.A., T.P. Navarro, R.W. Telles, L.E. Andrade, and E.I. Sato. 2007. Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8 weeks controlled trial. Rheumatology (Oxford) 46: 1560\u20131565.","journal-title":"Rheumatology (Oxford)"},{"key":"1455_CR211","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.atherosclerosis.2015.08.030","volume":"243","author":"HH Yu","year":"2015","unstructured":"Yu, H.H., P.C. Chen, Y.H. Yang, L.C. Wang, J.H. Lee, Y.T. Lin, and B.L. Chiang. 2015. Statin reduces mortality and morbidity in systemic lupus erythematosus patients with hyperlipidemia: a nationwide population-based cohort study. Atherosclerosis 243: 11\u201318.","journal-title":"Atherosclerosis"},{"issue":"1","key":"1455_CR212","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/art.30645","volume":"64","author":"LE Schanberg","year":"2012","unstructured":"Schanberg, L.E., C. Sandborg, H.X. Barnhart, S.P. Ardoin, E. Yow, G.W. Evans, K.L. Mieszkalski, N.T. Ilowite, A. Eberhard, L.F. Imundo, Y. Kimura, E. von Scheven, E. Silverman, S.L. Bowyer, M. Punaro, N.G. Singer, D.D. Sherry, D. McCurdy, M. Klein-Gitelman, C. Wallace, R. Silver, L. Wagner-Weiner, G.C. Higgins, H.I. Brunner, L. Jung, J.B. Soep, A.M. Reed, J. Provenzale, and S.D. Thompson. 2012. Use of atorvastatin in systemic lupus erythematosus in children and adolescents. Arthritis & Rheumatology 64 (1): 285\u2013296.","journal-title":"Arthritis & Rheumatology"},{"issue":"9","key":"1455_CR213","first-page":"961","volume":"30","author":"SM Yuan","year":"2020","unstructured":"Yuan, S.M. 2020. Coronary Artery Bypass Grafting in Patients with Systemic Lupus Erythematosus. Journal of College of Physicians And Surgeons Pakistan 30 (9): 961\u2013965.","journal-title":"Journal of College of Physicians And Surgeons Pakistan"},{"issue":"3","key":"1455_CR214","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1177\/0961203320904779","volume":"29","author":"T Liu","year":"2020","unstructured":"Liu, T., N. Shi, S. Zhang, G.J. Silverman, X.W. Duan, S. Zhang, and H. Niu. 2020. Systemic lupus erythematosus aggravates atherosclerosis by promoting IgG deposition and inflammatory cell imbalance. Lupus 29 (3): 273\u2013282.","journal-title":"Lupus"},{"issue":"6","key":"1455_CR215","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.4049\/jimmunol.1600108","volume":"199","author":"JJ Buie","year":"2017","unstructured":"Buie, J.J., L.L. Renaud, R. Muise-Helmericks, and J.C. Oates. 2017. IFN-\u03b1 Negatively Regulates the Expression of Endothelial Nitric Oxide Synthase and Nitric Oxide Production: Implications for Systemic Lupus Erythematosus. The Journal of Immunology 199 (6): 1979\u20131988.","journal-title":"The Journal of Immunology"}],"container-title":["Inflammation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10753-021-01455-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10753-021-01455-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10753-021-01455-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T07:43:09Z","timestamp":1632382989000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10753-021-01455-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,5]]},"references-count":215,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["1455"],"URL":"https:\/\/doi.org\/10.1007\/s10753-021-01455-6","relation":{},"ISSN":["0360-3997","1573-2576"],"issn-type":[{"value":"0360-3997","type":"print"},{"value":"1573-2576","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,5]]},"assertion":[{"value":"24 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}